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Understanding Immunosenescence in Aging-Related Diseases 
 With Quantitative Proteomics 
Zhiyun Cao, PhD 
University of Pittsburgh, 2014 
Immunosenescence refers to the gradual deterioration of the immune system during 
aging. It is widely accepted that immunosenescence is characterized by diminished immune 
response, low-grade inflammation, and increased propensity for autoimmunity. These changes in 
the immune system increase the risk and mortality of diseases among the elderly. Poor response 
to immunotherapies as a result of immunosenescence can further worsen this situation. 
Fundamental understanding of immunosenescence is helpful for the prevention and treatment of 
aging-related diseases. Genomics, transcriptomics, proteomics, and metabolomics can give 
insight to molecular mechanisms of immunosenescence and its contribution to aging-related 
diseases. In particular, work presented in this dissertation takes advantage of proteomics methods 
to understand immunosenescence in two aging-related diseases-sepsis and Alzheimer’s disease 
(AD).         
        To better study sepsis and AD, novel proteomics platforms are developed in this 
dissertation. Firstly, a robust platform is developed to improve the coverage of the human plasma 
proteome and establish statistical criteria for the determination of differentially-expressed 
proteins. Secondly, a novel data acquisition method using pulsed Q dissociation (PQD) in triple-
stage mass spectrometry (MS3) is developed for isobaric tags-based quantitation. This method 
increases the number of identified and quantified proteins without compromising quantitative 
accuracy.  
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       In sepsis studies, proteins involved in inflammation, acute phase response, coagulation, and 
lipid metabolism are associated with age-related risk of severe sepsis among community-
acquired pneumonia patients. In AD studies, a human double transgenic knock-in amyloid 
precursor protein/presenilin-1 (APP/PS-1) mouse model is employed. The proteome of T-cells 
and other immune cells (e.g., B-cells and macrophages) from this model is characterized and 
provides a reference map for future studies. T-cells from APP/PS-1 mice have increased 
oxidative stress during the progression of AD. Proteomics analysis of T-cells from this mouse 
model provides molecular basis for this phenomenon. Proteins related to cytoskeleton, energy 
metabolism, apoptosis, and molecular chaperones are also differentially expressed during AD 
progression. 
        Overall, works in this dissertation provide novel platforms for protein identification and 
quantitation. Application of proteomics platforms to the studies of sepsis and AD provides 
insight to the molecular mechanisms of immunosenescence. Results from these studies may be 
helpful for the development of novel diagnosis and treatments. 
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1.0 INTRODUCTION 
1.1 IMMUNOSENESCENCE AND AGING-RELATED DISEASES 
1.1.1 Aging and Immunity  
Aging is associated with progressive decline in physiological functions such as weakened 
muscle and bone strength, dysfunctional organs and immune system, and reduced metabolic 
rate1,2. These changes make the elderly, defined as aged 65 years and older, more susceptible to 
diseases including cancer, infectious diseases, and degenerative disorders. For example, the 
incidence and mortality of cancer is ~ 25- and 40-fold, respectively, in people older than 65 years 
compared to younger individuals3,4. Alzheimer’s disease (AD) occurring in people older than 65 
years accounts for ~ 90% of cases, although it can happen in early adulthood5. The elderly also 
have higher risk of comorbidities which further increases their mortality6. Management of the 
elderly has generated heavy economic burden. This situation will worsen as the population ages.  
It is estimated that between 2000 and 2050, the number of people 65 and 85 years and older will 
increase by 135% and 350%, respectively, in the United States7. Better understanding of aging 
and aging-related diseases is necessary to attenuate the burden caused by the increasing number 
of elderly persons. 
 Age-related impairment of the immune system is an important contributor to the 
increased incidence and mortality of diseases in the elderly. The immune system can protect 
individuals from pathogen invasion and maintain homeostasis. However, the functions of the 
immune system change during aging, which is termed immunosenescence.  Indeed, the elderly 
have reduced ability to fight against infections8-10. This is caused by defects in both the innate 
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and adaptive immune system such as reduced phagocytic capacity of macrophages and restricted 
T- and B-cell diversity8-10. In addition, aging is accompanied with low-grade chronic 
inflammation, which may cause inadvertent damage to organs11,12. For example, increased 
plasma levels of pro-inflammatory proteins increases the risk of cardiovascular disease while 
healthy aging is associated with relatively low levels of inflammation13. Immunosenesence also 
results in poor response to treatment11. In particular, vaccination is an important intervention for 
disease control and has been used effectively in children and younger adults11. However, the 
beneficial effects of vaccines are limited in the elderly due to dysfunctional B- and T-cells11. 
This again increases the incidence and mortality of diseases in this population.  
 Overall, because human aging is unavoidable, it is necessary to understand changes 
associated with this process in hopes to achieve healthy aging and prevent aging-related diseases. 
Accomplishment of this goal can be facilitated by the fundamental understanding of 
immunosenesence as it plays crucial roles in the incidence and mortality of aging-related 
diseases. Findings about immunosenesence may also provide insight to the prevention and 
treatment of aging-related diseases. Specifically, in this dissertation, the roles of 
immunosenesence in sepsis and AD are studied. Results presented in this dissertation have 
helped to generate a more complete picture about the immunopathology of these two diseases.  
 
1.1.2 Immunosenescence and Sepsis 14*  
(*note that part of the information shown in this section is written based on the published paper, Cao, Z.; 
Robinson, R. A. S. Proteomics-Clinical Applications 2014, 8, 35) 
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Sepsis is the systemic inflammatory response syndrome (SIRS) accompanied by 
infection15-17 (Figure 1.1). Infections can be caused by pathogens, including Gram-negative or 
Gram-positive bacteria, fungi, parasites, and viruses as well as secondary infections that occur as 
a result of nonpathogenic insults, such as trauma and burns15-17. The addition of at least one 
organ dysfunction denotes severe sepsis and subsequent hypotension despite adequate fluid 
resuscitation and/or the use of vasopressor denotes septic shock15,17 (Figure 1.1). From SIRS, 
sepsis, severe sepsis, to septic shock, there is a hierarchical continuum of inflammatory response 
to infection and increasing mortality rates18. For example, severe sepsis and septic shock have 
mortality rates of 27.3 and 36.4%, respectively19. Comorbidities in sepsis patients can exist. For 
example, cutaneous adverse drug reaction20, urinary tract infection21, and community-acquired 
pneumonia (CAP)22 are the most common causes of SIRS, sepsis, and severe sepsis, 
respectively. The most severe cases of infection lead to multiple organ dysfunction syndrome 
(MODS) and without positive response to treatment, death23.   
To slow inflammatory response and reduce mortality rates, it is important to develop 
efficient therapeutic strategies for patients with sepsis. Currently, antimicrobial treatments and 
early goal-directed therapy play important roles in the management of sepsis24-26. However, their 
applications in clinical practice are limited. For example, the choice of a specific antimicrobial 
treatment can be influenced by the infection site and molecules released from microorganisms 
may exacerbate inflammatory response24,25. Several therapies- glucocorticoids27, recombinanat 
human-activated protein C28, steroids29, intravenous Ig30, continuous renal replacement therapy31, 
proinflammatory cytokine inhibitors24, antioxidant supplementation32, and others33-35-have been 
targeted at sepsis without much success. Overall, more than 40 clinical trials of therapies targeted 
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Figure 1.1. Diagram illustrating the progression of septic infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
SIRS sepsis severe sepsis
Most Common Causes
cutaneous adverse 
drug reaction 
urinary tract 
Infection 
community-acquired
pneumonia
Diagnostic Criteria
the presence of two or 
more of the following:
• fever or hypothermia
• tachycardia
• tachypnea
• leukocytosis or 
leukopenia
presence of infection 
accompanied with SIRS
sepsis and one or more 
organ dysfunction
• acute lung injury
• coagulation 
abnormalities
• thrombocytopenia
• renal, liver, or cardiac 
failure
• hypoperfusion with 
lactic acidosis
sepsis and hypotension
despite adequate fluid 
resuscitation and/or the 
use of vasopressor
septic shock MODS
≥ 2 organ dysfunction
Non-infectious insults
(e.g., burns, surgery )
Infectious insults
death
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at septic patients have failed to lead to a current FDA-approved drug for the universal treatment 
of sepsis.  
 The lack of current universal treatment for sepsis can be understood due to the many 
challenges associated with this condition. Diagnosis of sepsis is complicated by the different 
faces in which it can present itself among patients (i.e., degree and nature of clinical symptoms 
can vary tremendously). In addition to patient heterogeneity, there is also temporal heterogeneity 
within individual patients36. The timing of the diagnosis is crucial to initiation of therapy, 
however, this is difficult because the assays for culture determination can take as long as 48 h17 
and some patients have symptoms for a day prior to hospital admission37. In more than half of 
the cases, clinical symptoms persist without a positive culture17. Monitoring of specific 
biomarkers (e.g., tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-8, and IL-10, 
procalcitonin, C-reactive protein, and others) yield conflicting results with regards to sensitivity, 
specificity, and effectiveness in both adults and neonates17. Because of the roles of many of these 
molecules in immune response and inflammation, a single readout of any specific biomarker can 
be misleading. Biomarker readouts are heavily time-dependent as there is a known acute 
proinflammatory response that occurs in the first 24 h after infection37. Challenges with 
diagnosis, prognosis, and real-time response to treatment of sepsis-which warrant the 
development of novel therapeutics and strategies-can be best facilitated by understanding the 
molecular mechanisms of this condition.   
Different tools have been used to investigate molecular mechanisms of sepsis, including 
genomics, transcriptomics, proteomics, metabolomics, and protein immunoassays38,39. In 
particular, proteomics studies have attracted more attention in the last few decades and unveiled 
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numerous information underlying this infection40,41. One beneficial aspect of proteomics studies 
is that they can be applied to tissues that arise from sepsis patients or animal models and give 
insight to host response. Models of sepsis have been developed in rodents (e.g., mice and rats), 
larger mammals (e.g., pigs and cats), and in humans (e.g., injection of endotoxins or 
exotoxins)41,42.  
To date, it is widely accepted that sepsis consists of both a proinflammatory response and 
an anti-inflammatory counter response that happens at the onset of infection and days afterward, 
respectively17,34. At the onset of sepsis, pathogens are recognized by immune cells resulting in 
the activation of inflammatory response and a cytokine cascade17. In addition to the increased 
levels of cytokines, elevated concentrations of cell surface receptors (e.g., toll like receptors, 
CD14 antigen) and acute phase proteins (e.g., serum amyloid A proteins, LPS binding proteins, 
and glycoproteins) are increased in response to sepsis14. Persistent proinflammation in sepsis 
patients may lead to death43. For those who survive from the initial inflammation, suppressed 
immune response may develop34,43. This immunosuppression is manifested with increased 
apoptosis of macrophages, B-cells, and T-cells, enhanced suppressive property of regulatory T-
cells, and elevated levels of anti-inflammatory cytokines34,43. Immunosuppression in sepsis leads 
to the inability to clear primary infection and the development of secondary infection34,43.   
Inflammation in sepsis patients results in activation of the pro-coagulation pathway, 
which causes a proteolytic cascade that increases production of blood clots and contributes to 
organ failure23,44. Sepsis patients and animal models have higher levels of fibrinogen and von 
Willebrand factor, which enhances the formation of blood clots14. In addition, an inhibited anti-
coagulant pathway manifested by decreased levels of related proteins (e.g., anti-thrombin and 
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heparin factor-2) is associated with sepsis14. Promoted coagulation in sepsis can in turn 
exacerbate inflammation. For example, thrombin, which is involved in coagulation, can activate 
monocytes and endothelial cells and induce the production of pro-inflammatory cytokines. 
Sepsis also has negative impact on cells and tissues. Reactive oxygen species (ROS) and reactive 
nitrogen species (RNS), which are produced from neutrophils, macrophages, and other 
leukocytes, subsequently lead to a buildup of toxic species that can target proteins, lipids, and 
DNA in host tissues resulting in oxidative damage45,46.  
 While sepsis affects people at different ages, the elderly is the most susceptible 
population to sepsis. Out of ~ 750,000 people diagnosed with sepsis annually, more than 60% of 
patients are older than 65 years old accounting for ~ 52% of the annual healthcare resources 
generated by sepsis47. An epidemiological study showed that the incidence of sepsis among 
people > 85 years old is > 100 times higher than that in children16. CAP patients ≥ 85 years old 
have a 3-fold increased risk of severe sepsis compared to those ≤ 50 years old48. Aging is also a 
contributing factor to the increased mortality rates of sepsis in the elderly. For example, among 
the patients hospitalized with CAP-induced severe sepsis, the mortality rate for patients ≥ 85 
years old increased by ~ 8-fold compared to those ≤ 50 years old48. Sepsis patients ≥ 65 years old 
have 3-fold increased mortality compared to those < 65 years old49.  
 Although various factors (e.g., impaired performance status, dysregulated nutrition 
sensing, and reduced social activity) may contribute to age-related incidence and mortality of 
sepsis, immunosenescence plays essential roles. In particular, involution of thymus in the elderly 
results in a significantly reduced number of naïve T-cells8,47,50. Naïve T-cells from the elderly 
have restricted T-cell receptor repertoires, reduced production of IL-2, and impaired ability to 
7 
 
  
differentiate into effector cells8,47,50. B-cell activation and production of antibodies is reduced in 
the elderly as well as antibody affinity to antigens2,24,25. These changes compromise the effective 
immune response to new antigen invasion in the elderly and increase their susceptibility to 
sepsis. Persistent low-grade inflammation in the elderly also increases the risk of sepsis by 
inducing the expression of cell surface receptors and promoting the host response to pathogens51. 
 The effect of aging on the immune system in sepsis has also been examined. An aged 
mouse model of sepsis has higher levels of pro-inflammatory cytokines (e.g., IL-6 and TNF-α) 
and coagulant proteins (e.g., fibrinogen) relative to younger sepsis mice. The elevated levels of 
these proteins in aged mice correlates with higher mortality52-54. However, discrepant results 
have been obtained in human studies. For example, at day 1 of hospital stay, the levels of IL-6 
and IL-10 are similar between CAP patients from age groups of > 85 and < 65 years old55. CAP 
patients from different age groups (i.e., < 50 years, 50-64 years, 65-74 years, 75-84 years, and ≥ 
85 years) have similar levels of IL-6, TNF-α, IL-10, D-dimer, and anti-thrombin at day 1 and 
over the first week of hospitalization, although age-related risk and mortality of severe sepsis 
occurs in the same cohort of CAP patients48. Similarly, patients hospitalized with Streptococcus 
pneumonia infection have no age-related difference in the levels of IL-6 and TNF-α at day 156.  
However, increased levels of TNF-α are found at day 7 in the elderly which implies that old age 
is associated with prolonged inflammatory response56.   
 Elderly patients with sepsis also have poor long-term outcomes. CAP patients > 85 years 
have a 1.3- and 2-fold increased risk of 1-year post-discharge mortality than those 75-84 years 
and 65-74 years, respectively48. This may be related to persistent inflammation and coagulation 
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in the elderly. Higher levels of IL-6 and D-dimer in older patients at hospital discharge are 
associated with increased mortality51.  
 Overall, age-related effects on the immune system are involved in the stages before, 
during, and after sepsis. Better understanding these effects is beneficial for the development of 
more efficient methods for disease prevention and treatment. However, current studies only 
focus on a set of selected proteins involved in inflammation and coagulation. Globally studying 
changes in proteins between different age groups will generate a more complete picture about 
age-related risk and mortality of sepsis patients. 
 
1.1.3 Immunosenescence and Alzheimer’s Disease 
 AD is a neurodegenerative disorder characterized with progressive memory defects, 
cognitive impairment, and changes in behavior and personality12,57. AD is an aging-related 
disease with the incidence increasing almost exponentially after 65 years old57. A 2005 
epidemiological study shows that ~ 27 billion people are diagnosed with AD worldwide57. This 
number will increase by four-fold by 205057. Early diagnosis of AD is challenging since evident 
clinical symptoms of AD usually appear at the late stage of this disease. Currently, drugs (e.g., 
galantamine, donepezil, rivastigmine, tacrine, and memantine) regulating neurotransmitters are 
used to relieve the symptoms of AD58,59. However, these drugs cannot stop or reverse the 
progression of AD58,59. Therefore, better understanding of AD pathology is necessary for the 
development of novel diagnostic and therapeutic methods.   
Much effort has been made to understand changes in AD brain. Two major pathological 
hallmarks of AD are the accumulation of senile plaques (SP) and neurofibrillary tangles 
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(NFT)12,57. SP are composed of amyloid β (Aβ) peptides which are generated from the 
proteolysis of amyloid precursor protein (APP) by β- and γ-secretases12,57. Hyperphosphorylated 
tau-proteins are components of NFT12,57. The central nervous system (CNS) in AD also has 
regionalized neuronal death, loss of synaptic connections, increased oxidative stress, 
mitochondrial dysfunction, and reduced energy metabolism60-63.  
Neuroinflammation is another important hallmark of AD12,64. Initial inflammatory 
response by microglia and astrocytes, two types of immune cells resident in the CNS, is 
beneficial for the clearance of Aβ plaques64. However, in AD, Aβ plaques trigger chronic 
neuroinflammation manifested by over-activated microglia and astrocytes and elevated levels of 
pro-inflammatory cytokines, chemokines, and acute phase proteins12,64. This chronic 
inflammation, in turn, enhances the production of Aβ plaques12,64. It is unknown whether 
neuroinflammation is a cause or a consequence of AD, however, it is clear that 
neuroinflammation and Aβ production are involved in a self-propagating feedback loop with 
adverse outcomes12,64.  
While changes in the CNS are closely related to AD, cumulative evidence suggests the 
involvement of the peripheral immune system in the pathogenesis of AD. Low-grade 
inflammation associated with immunosenescence in the elderly may increase susceptibility to 
AD11,12. Inflammation caused by infectious agents also contribute to the incidence of AD and 
this effect is enhanced in the elderly due to diminished ability to control infection65. Non-
steroidal anti-inflammatory drugs (NSAID) have significantly reduced risk of AD which 
provides additional proof for the involvement of the immune system in AD12. 
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 However, clinical trials of NSAID on people who are already diagnosed with AD do not 
give promising results12. This may be explained by the further impaired immune system in AD. 
In AD, a compromised blood-brain barrier (BBB) allows the efflux of Aβ oligomers and pro-
inflammatory mediators to the periphery, which induces the peripheral immune response12,66. 
Immune cells (e.g., T-cells and monocytes) from AD patients are activated and secrete increased 
levels of proinflammatory cytokines12,66. These cytokines can cross the BBB and promote 
neuroinflammation and Aβ production12,66.  Communication between the CNS and peripheral 
immune system also alters the distribution of immune cells. Peripheral immune cells in CNS 
regions that contain Aβ deposits are present in AD67. These cells may also exacerbate 
neuroinflammation. In the periphery, a decreased number of B-cells has been observed in AD12. 
AD patients have a decreased number of naïve T-cells and increased number of memory T-
cells12. Subpopulations of T-cells also change in AD patients, although conflicting results exist12. 
The function of immune cells is impaired in AD. Macrophages and monocytes have lessened 
phagocytic ability68,69. The cytotoxic function of natural killer cells is impaired although no 
changes are observed in the number of natural killer (NK) cells70. B-cells have reduced anti-Aβ 
response12. T-cells have elevated calcium response, increased apoptosis, and hyper-activity71-73. 
Findings in the peripheral immune system provide more insight into the pathology of AD. 
Additionally, these can be used as potential peripheral biomarkers for disease diagnosis and 
prognosis in the periphery. Compared to the biomarkers in the brain, peripheral biomarkers are 
more easily obtainable.  
   It is clear that the peripheral immune system is involved in the pathology of AD. 
However, characterization of the peripheral immune system in AD is far from complete. Animal 
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models of AD offer an important means to gain more insight into the immunopathogenesis of 
this disease and in fact dysfunction of the immune system in various mouse models has been 
reported. The triple transgenic (3xTg) AD mouse model has increased production of senile 
plaques and neurofibrillary tangles in the brain74. In 3xTg mice, reduced weight of immune 
organs (e.g., thymus, spleen, and adrenal glands) indicates their premature immunosenescence74. 
3xTg mice have decreased chemotaxis, anti-tumoral NK activity, and IL-2 secretion74 and show 
signs of systemic autoimmunity75. Regulation of the inflammatory response by blocking IL-1 
signaling attenuates cognitive defects in 3xTg mice76. In this dissertation, a human double 
transgenic knock-in amyloid precursor protein/presenilin-1 mouse model (hereafter referred to as 
APP/PS-1) is employed77,78. APP/PS-1 mice show age-dependent progression of AD77,78. 
Specifically, Aβ plaques start to deposit in the brain of APP/PS-1 mice at six months, and they 
mimic the cognitive deficits associated with early stage AD77,78. By 12 months of age, numerous 
SP are present in the hippocampus and caudal cortex, which corresponds to late stage AD77,78. 
Consistent with findings about human AD, APP/PS-1 mice have increased oxidative stress in 
brain and neurons79,80. They have an impaired immune system indicated by increased activation 
of microglia81,82, altered monocyte subpopulations83, and enhanced cell proliferation of 
lymphocytes84. APP/PS-1 is a useful model in elucidating immunopathogenesis in AD. 
 Understanding immunosenescence in AD provides insight to the development of novel 
immunotherapies for this disease. According to the Aβ hypothesis of AD, the clearance of Aβ 
plaques may aid the recovery of cognitive function. Immunization of APP transgenic mice with 
Aβ prior to the onset of AD hallmarks significantly reduces levels of Aβ plaques in the brain85. 
Immunization with Aβ also decreases the levels of Aβ plaques in aged APP transgenic mice86. 
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More importantly, this reduction in Aβ plaques prevents age-related cognitive defects86. These 
results provide an encouraging means for AD prevention and treatment. Clinical application of 
Aβ immunization reduces Aβ plaques in AD patients87. However, these patients immunized with 
Aβ have significanly increased risk of developing encephalitis87. Although the mechanisms for 
this observation are still unclear, it has been suggested that over-activation of T-cells in response 
to Aβ immunization is an important contributor87. Therefore, fundamental understanding of the 
changes in the immune system in AD will be helpful to develop effective therapies.  
  
 In conclusion, immunosenescence is an important contributor to sepsis and AD.  
Currently, systematic biological methods from genomics, transcriptomics, proteomics, to 
metabolomics are being used in studies about aging and aging-related diseases. In particular, 
proteomics is the study focusing on the whole set of proteins in a biological system. Proteomics 
has been employed to understand the molecular mechanisms associated with immunosenescence, 
sepsis and AD. For example, proteomics studies have revealed that immunosenescence is 
associated with increased oxidative stress in B- and T-cells88. In sepsis, changes in organ 
proteome (e.g., liver and kidney) give insight into sepsis-induced organ dysfunction89,90. 
Proteomics studies about AD brain and cerebrospinal fluid have been done to investigate 
pathology of this disease61,91-95. In addition, biomarker candidates for sepsis and AD diagnosis 
and prognosis have been discovered in plasma and urine by proteomics studies14,96,97. Biomarker 
candidates in these tissues are attractive due to their easy accessbility. In this dissertation, 
proteomics technologies are employed to study alterations in sepsis and AD. 
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1.2 SHOTGUN PROTEOMICS TECHNOLOGIES 
1.2.1 Shotgun Proteomics 
Proteomics refers to the study of the whole set of proteins in a biological system (e.g., 
biofluids, tissues, and cells)98. Proteomics studies can provide information about protein 
abundance, distribution, post-translational modification, function, and interaction99. Shotgun or 
“bottom-up” proteomics technologies, which identify proteins based on their proteolytic 
peptides, is employed in this dissertation. In a typical shotgun proteomics workflow, proteins 
extracted from biological tissues are digested with a protease (i.e., trypsin) to generate peptide 
mixtures, which are separated using liquid chromatography (LC) and electrosprayed into a mass 
spectrometry (MS) instrument. In the parent MS scan, intact peptide ions are detected and their 
m/z ratios are recorded. Peptide ions are further isolated and subject to collision induced 
dissociation (CID) to generate tandem mass spectra (MS/MS), in which b- and y-type fragment 
ions (Figure 1.2) are detected. Mass difference between adjacent b- or y-ions can be used to 
identify amino acid residues in peptide sequences. Database search algorithms (i.e., 
SEQUEST100, as described below) are used to identify peptides and their corresponding proteins. 
 
1.2.2 Isobaric Tagging Methods 
One important research interest in the field of proteomics is to obtain differences in the 
relative abundance of proteins between different conditions (e.g., disease vs. healthy). Currently, 
there are many quantitative proteomics methods available101-103. Among these methods, isobaric 
tags offer the advantage to quantify up to ten samples simultaneously104-106, which significantly 
reduces instrument acquisition time. More importantly, multiplexing also decreases experimental 
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Figure 1.2. The diagram of b- and y-ions produced by CID fragmentation. 
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error caused by multiple sample preparation steps and handling. In this dissertation, isobaric tags 
for relative and absolute quantitation (iTRAQ)102 (Chapters 2, 4, and 7) and tandem mass tags 
(TMT)107 (Chapter 3) are employed for protein quantitation. iTRAQ and TMT are similar and 
contain three chemical groups in the structure: reporter ion group, balancer group, and amine 
reactive group (Figure 1.3a). Herein, iTRAQ 4-plex is used as an example to illustrate the 
principle of isobaric tags (Figure 1.3b). Four different reagents which have the same structure 
and mass are synthesized. Heavy isotope atoms (e.g., 13C, 15N, and 18O) are incorporated into the 
reporter and balancer group to keep the overall mass of these two parts identical (e.g. 145 Da). 
The mass of the reporter group ranges from 114 to 117 Da, and the mass of the corresponding 
balancer group ranges from 31 to 28 Da. The incorporation of 13C, 15N, and 18O does not change 
the physical or chemical properties of the labeled peptides, and has no effect on LC separation. 
N-hydroxysuccinimide is used as a peptide reactive group, and it can react with free primary 
amino groups (i.e., N-termini and lysine residues, Figure 1.3c). In the iTRAQ-based proteomics 
experiment (Chapters 2 and 7), peptides generated from four biological samples are labeled with 
different iTRAQ 4-plex reagents. After iTRAQ-labeling, these four peptide mixtures are 
combined and subject to LC-MS/MS analysis. The same peptides labeled with different iTRAQ 
reagents elute from the LC column, are ionized and detected in the MS simultaneously. The 
parent MS scan shows a single unresolved peak for these peptides. This peak is isolated and 
fragmented to generate reporter ions [i.e., mass-to-charge (m/z) 114, 115, 116, and 117), which 
are detected in the MS/MS spectrum. The existence of isotopic impurities needs to be corrected 
to generate accurate reporter ion intensity. For example, peak intensity for reporter ion at m/z 114  
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Figure 1.3. a) The general composition of isobaric tags, b) structure and isotopic atom composition of 
iTRAQ 4-plex, and c) the reaction between peptides and iTRAQ reagents. 
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contributed from adjacent reporter ions (e.g., m/z 115) should be corrected. The peak intensity 
for these reporter ions is used to quantify peptides. Protein ratios are obtained using the median 
ratios of their corresponding peptides.  
 
1.2.3 Separation and Mass Spectrometry  
MS represents a powerful tool with high sensitivity, specificity, and through-put and 
plays a central role in proteomics studies. Coupling of separation technologies, for example, LC, 
can result in hundreds of proteins identified in one single proteomics experiment. Multi-
dimensional protein identification technology (MudPIT) has been developed to increase the 
number of identified peptides and proteins108, which allows to more depth into the proteome of 
biological systems. In this MudPIT experiment, online strong cation exchange (SCX) and reverse 
phase (RP) LC are employed to sequentially separate peptides based on their charge and 
hydrophobicity108.  Offline SCX-RP LC separation, which offers advantages of high flexibility 
and more comprehensive proteome coverage109, however, is used in the bulk of work in this 
dissertation (Chapters 2, 4, 5, and 7).  One-dimensional RPLC separation is also employed 
(Chapter 3). For other separation techniques used in proteomics studies, we refer the readers to 
the references as follows110-113.   
SCX separation is carried out on a PolySulfethyl A column. Acidic pH of the mobile 
phase buffers makes the basic amino acid residues and N-termini positively charged. This helps 
the retention of peptides on the stationary phase by electrostatic forces. Addition of organic 
solvent (i.e., acetonitrile) in the mobile phase buffers helps the retention of peptides on the 
stationary phase by hydrophobic interactions. To elute peptides from the stationary phase, a 
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gradient with increasing concentration of salt (i.e., KCl) is used. Peptides with more positive 
charges are eluted later. Eluents from the SCX separation are collected every minute and pooled 
to generate a user-determined number of fractions. Each SCX fraction is desalted using solid-
phase extraction techniques, dried, and reconstituted in an appropriate solution for online RP-
LC-MS/MS analysis. RP separation is carried out on a home-made capillary column packed with 
C18 material. In RPLC, peptides are retained on the stationary phase by hydrophobic interaction 
and eluted by increasing the composition of organic solvent (i.e., acetonitrile) in the mobile 
phase.  
 Eluents from RPLC are electrospray ionized (ESI)114 and introduced into a commercial 
mass spectrometer, LTQ-Obitrap Velos. LTQ-Orbitrap Velos is a hybrid instrument with two 
mass analyzers-linear ion trap (LTQ) and Orbitrap103. Data-dependent acquisition (DDA) is used 
to acquire peptide information. Specifically, ions eluted at one retention time are detected in the 
Orbitrap to generate a parent MS scan with high resolution (i.e., 60,000 at m/z 400) and mass 
accuracy (i.e., < 10 ppm). The most intense peak in the parent MS scan is isolated and 
fragmented in the LTQ. B- and y- type fragment ions can be detected in the LTQ or Orbitrap. 
This is followed by CID fragmentation of the second most intense peak, the third, and so forth. 
Dynamic exclusion is enabled in this data acquisition process such that peptide ions with the 
same m/z are not detected multiple times within a time window. Dynamic exclusion allows the 
detection of low-abundance peptides, which increases the number of identified peptides and 
proteins. Many of the features in DDA are user-defined for a particular experiment.  
CID MS/MS in the LTQ provides information for peptide identification. However, this 
method is not suitable for iTRAQ quantitation. This is due to their low mass cutoff limitation, 
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preventing the trapping of fragment ions with m/z values lower than the 25-30% of the parent 
ion115. The detection of iTRAQ reporter ions with m/z 114-117 is not possible in CID 
fragmentation115. To overcome this, higher energy collision induced dissociation (HCD) is 
employed, whereby peptide ions are fragmented in the HCD collision cell and fragment ions are 
detected in Orbitrap. HCD provides good fragmentation efficiency for reporter ions, however, b- 
and y- ion coverage is compromised115. Therefore, combination of CID and HCD (CID-HCD)115 
are used for peptide identification and quantitation (Chapters 2, 4, and 7).  
 
1.2.4 Protein Identification and Quantitation 
The raw data collected from shotgun proteomics analysis is processed by database search 
algorithms (i.e., SEQUEST100) to generate a list of proteins and peptides present in the original 
sample. In this process, SEQUEST100 digests proteins from a given database in silico using the 
specified enzyme (i.e., trypsin) that is used experimentally. Experimental and theoretical MS/MS 
spectra are compared and scores (e.g., Xcorr) which evaluate their similarities are returned. 
Search parameters such as mass tolerance of the parent and fragment ions and static or dynamic 
modifications (i.e., oxidation on methionine, iTRAQ labeling on N-termini and lysine, etc.) can 
affect these values. Searching against decoy or reverse databases (i.e., databases with reversed 
protein sequences) is used to determine the false-discovery rate (FDR) for protein and peptide 
identification. Typical FDR values used in the assignment of peptides are 0.05 and 0.01, which 
indicate 95% and 99% confidence in peptide identification, respectively (i.e., 1 in 20 or in 100 
assignments are false positives). SEQUEST is built into a software called Proteome Discoverer 
(PD, Thermo Scientific) for protein and peptide identification. PD has functions to extract 
20 
 
  
iTRAQ or TMT reporter ion intensities from raw data for peptide quantitation. The median value 
of peptide ratios is calculated for each protein and for comparisons across different samples. To 
determine the proteins which are statistically different in relative concentration between samples, 
student’s t-test, analysis of variance (ANOVA), and power analysis can be employed. Multiple 
test correction (e.g., Bonferroni correction) is also necessary to control FDR. Generally, tens to 
hundreds of proteins which have varied concentrations between different conditions will be 
identified. Biological function analysis of these proteins using softwares such as Gene 
Ontology116 and Ingenuity® System is helpful to gain insight into the molecular mechanisms of 
diseases. 
 
1.2.5 Immunodepletion of Human Plasma 
Human plasma is widely used in disease studies. It offers several advantages. Firstly, it is 
easy to collect. Secondly, human plasma is informative. Besides the classical proteins (e.g., 
albumin, IgG), human plasma also contains proteins secreted from different organs and cells117. 
It is believed that alterations in the levels of proteins from organs and cells may reflect the 
disease state of individuals. However, detection of these proteins is challenging due to their low 
concentrations and the high dynamic range in human plasma (~ 1010-1012). Various methods 
have been developed to increase the identification of low-abundance proteins, such as, 
immunodepletion of high-abundance proteins117 and equalization of protein concentrations using 
combinatorial ligand libraries118 or molecular weight cutoff filters119. In this dissertation, an 
immunodepletion method, multiple affinity removal system (MARS), is employed.  MARS is a 
LC column containing antibodies targeting the six most abundant proteins in plasma (i.e., 
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albumin, IgG, IgA, transferrin, haptoglobin, and anti-trypsin). To deplete high-abundance 
proteins more efficiently, a method, termed as tandem MARS depletion (TMD), has been 
developed, in which the flow-through fraction containing low-abundance proteins from the first 
MARS depletion is followed by another MARS depletion (Chapters 2 and 4). Flow-through 
fraction from TMD is used for further proteomics analysis.  
 
1.2.6 Immunoblotting Analysis  
 Two immunoblotting analysis methods are used in this dissertation: Western blot 
(Chapter 4 and 7) and slot blot (Chapter 6). Western blot is used as an independent method to 
verify protein ratios obtained from quantitative proteomics experiments. In Western blotting 
analysis, proteins are separated by polyacrylamide gel electrophoresis (PAGE) and transferred to 
a nitrocellulose membrane. Primary antibodies for targeted proteins are added to incubate with 
the membrane. This is followed by the addition of secondary antibodies which recognize the 
primary antibodies. Secondary antibodies are conjugated with alkaline phosphatase, which will 
develop colorometrically in the presence of 5-bromo-4-chloro-3’-indolyphosphate p-toluidine 
salt and nitrotetrazolium blue.  
Slot blot is employed to measure oxidative stress in biological systems. Aging and various 
diseases are associated with increased oxidative stress120-123. Oxidative stress occurs when the 
levels of ROS and RNS overwhelm the levels of antioxidants. ROS and RNS may damage 
molecules such as proteins, DNA, and lipids, which leads to the dysfunction of cells and organs. 
In this dissertation, protein oxidation is used as a read-out of oxidative stress, we refer the 
readers for oxidative damage to other molecules to the following references124-126. Oxidative 
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damage on proteins causes the formation of carbonyl groups (PCO) on the side chain of amino 
acid residues (e.g. proline, arginine, lysine, and threonine, Figure 1.4a)127. Nitration of tyrosine 
residues [i.e., 3-nitrotyrosine (3-NT), Figure 1.4a) is an important marker of protein oxidation. 
To measure the levels of PCO and 3-NT using slot blot, proteins derivatized with 2,4-
dinitrophenylhydrazine (DNPH) (Figure 1.4b) or without derivatizaion, respectively, are directly 
loaded onto a nitrocellulose membrane. Primary antibodies which target at PCO and 3NT are 
used to assess the oxidative stress, while secondary antibodies provide a detectable readout.  
 
1.3 OVERVIEW OF DISSERTATION 
This dissertation employs proteomics techniques to study immunosenescence in sepsis and 
AD. To better achieve this goal, a novel proteomics workflow for protein quantitation in human 
plasma is established (Chapter 2). New data acquisition methods for isobaric tagging are also 
developed to increase the number of proteins identified and quantified (Chapter 3). Finally, 
proteomics tools are used to investigate immunosenescence in sepsis (Chapter 4) and AD 
(Chapters 5-7). Plasma samples from sepsis patients and immune cells from APP/PS-1 mouse 
model are employed in sepsis and AD studies, respectively. Although gender affects the risk and 
mortality of sepsis and AD128,129, in this dissertation, its effects are not studied. Both male and 
female patients are enrolled in sepsis studies to obtain general information about 
immunosenescence in sepsis, whereas due to the easy accessibility of mice with different 
genders, only male APP/PS-1 mice are used in AD studies to exclude the gender-related effects. 
Based on the findings in Chapters 4-7, further direction for studies about sepsis and AD are 
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presented in Chapter 8. Chapters 2-7 are written directly as published papers or manuscripts, 
thus, there is redundant information of defining abbreviated terms. 
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Figure 1.4. a) the structure of carbonylated amino acid residues and 3-nitrotyrosine resulting from protein 
oxidation: 2-pyrrolidone from proline, glutamic semialdehyde from arginine and proline, α-aminoadipic 
semialdehyde from lysine, and 2-amino-3-ketobutyric acid from threonine. b) the reaction between 2,4-
dinitrophenylhydrazine (DNPH) and protein carbonyl groups (PCO).  
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2.0 ADDITIONS TO THE HUMAN PLASMA PROTEOME VIA A TANDEM MARS 
DEPLETION iTRAQ-BASED WORKFLOW130* 
(* note that information in this chapter is written based on a published paper, Cao, Z.; Yende, S.; Kellum, 
J. A.; Robinson, R. A. S. International Journal of Proteomics 2013, Article ID 654356) 
2.1 INTRODUCTION 
 Discovery studies using plasma proteomics present challenges due to the technical 
difficulties associated with measuring the large dynamic range (~ 10-12 orders of magnitude) of 
proteins that exist in the medium117. Low-abundance proteins, which are of interest for 
biomarker applications are often only accessible with involved proteomics workflows that utilize 
multiple sample fraction steps. While the development of specific clinical immunoassays would 
resolve this approach, much work needs to be done in this area. Enrichment strategies for low-
abundance plasma proteins rely on immunodepletion of high-abundance proteins131-133, and, 
more recently, tandem depletion strategies have been employed134-137. For example, proteins 
present in as little as 1-1.6 µg·mL-1 concentrations are detectable using tandem removal of 
abundant proteins with human serum albumin and Human 14 (Hu14) multiple affinity removal 
system (MARS) columns137. A two-stage depletion setup that involves serial IgY and Supermix 
columns has also been effective in increasing the number of detectable low-abundance proteins 
without affecting quantitative accuracy and precision using isobaric tags for relative and absolute 
quantification (iTRAQ)134. 
 Recently, an updated reference database of human plasma proteins was released from the 
Human Plasma Proteome Project (HPPP) which includes 1929 nonredundant protein 
sequences138. This list includes proteins that were identified amongst ~ 30 laboratories that 
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utilized various enrichment and depletion strategies, shotgun proteomics techniques, and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) platforms. Herein, we report additions 
to the released reference database based on results obtained from the analysis of plasma samples 
in our laboratory by a dual depletion shotgun proteomics technique.  
Quantitative proteomics analysis of plasma are useful for identifying clinically relevant 
biomarkers139 or in understanding disease mechanisms such as Alzheimer’s disease140. The 
inherent biological variability across human patients can require a large number of samples in 
order to determine differentially-expressed proteins that are statistically relevant. Depending on 
factors such as instrumental platform and available instrument time, multiplexing strategies are 
attractive. The commercial iTRAQ reagent allows up to eight samples to be multiplexed and has 
been effective in identifying biomarkers or differentially-expressed proteins in diseases141-143. 
Limitations to this quantitative approach can include cost of reagent kits and issues with 
underestimation of ratios144. 
Nonetheless, iTRAQ can provide reliable quantitative information depending on the 
statistical rigor required for denoting proteins as differentially expressed7,17-20. Several reports 
have stressed the importance of biological and technical replication in iTRAQ-based quantitative 
studies142,145-147. These reports however, do not converge on the same finite set of criteria for 
determining statistically relevant differentially-expressed proteins. For example, Song et al. 
suggest that at least 20 or eight biological samples are required in order to use fold-change cutoff 
values of 1.5 and 2.0, respectively146. Chee et al. employ a ± 30% or ± 50% cutoff for technical 
and biological replicates, respectively145. Most recently, a fold-change > two is deemed 
appropriate when at least six biological sample replicates are employed in order to have 
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sufficient statistical power148. That the criteria should even converge has also been questioned as 
it has been proposed that fold-change cutoff values are dependent on many factors: replications, 
number of observed peptides, protein class (e.g., high or low abundance), and so forth; specific 
values should be defined based on experimental goals and design149.  
Herein, we evaluate a robust tandem depletion quantitative proteomics workflow for its 
ability to provide additional insight to the human plasma proteome and to provide suitable 
criteria for the statistically relevant determination of differentially-expressed proteins in human 
plasma. 
 
2.2 MATERIALS AND METHODS  
2.2.1 Plasma Samples 
Four plasma samples were obtained from patients enrolled in the Genetic and 
Inflammatory Markers of Sepsis (GenIMS) study150. These patients were initially diagnosed with 
community-acquired pneumonia upon admittance to the emergency department, and samples 
were collected; however, further diagnosis revealed improper initial assessment. Thus these 
samples come from otherwise healthy volunteers. Approval for the participation of human 
subjects was obtained by the Institutional Review Board of the University of Pittsburgh and other 
participating sites. 
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2.2.2 Tandem MARS Immunodepletion (TMD)  
The Hu 6 MARS column depletes serum albumin, IgG, α-1-antitrypsin, IgA, transferrin, 
and haptoglobin proteins. An injection amount of 60 µL of crude plasma was applied to the 
MARS column (Agilent; Santa Clara, CA, USA), and after the initial depletion, flow-through 
fractions were concentrated with a 5K molecular weight cutoff concentrator (Agilent; Santa 
Clara, CA, USA) at 4695 g for 1.5 h. Samples (hereafter referred to as MD) were then stored at -
80 ºC or reinjected onto the MARS column for tandem MARS depletion. The second flow-
through fractions (hereafter referred to as TMD) were concentrated, and protein concentrations 
were measured using the BCA protein assay. 
 
2.2.3 Protein Digestion and iTRAQ Labeling  
In order to normalize experimental conditions, same amounts of protein (i.e., 100 µg) as 
determined from a BCA assay were employed. Protein amounts as opposed to sample volumes 
were used since the concentration of proteins in the flow-through fraction may vary across 
samples after TMD. A total of 100 µg of protein was denatured with an extraction buffer (0.2 M 
Tris, 8 M urea, 10 mM CaCl2, pH 8.0), reduced with 1 : 40 molar excess of dithiothreitol for 2 h 
at 37 ºC, and then alkylated with 1 : 80 molar excess of iodoacetamide for 2 h on ice in the dark. 
The alkylation reaction was quenched by adding 1 : 40 molar excess of cysteine, and the mixture 
was incubated at room temperature for 30 min. Molar excesses for each reagent was calculated 
based on an estimation of the total moles of proteins in each sample (i.e., average molecular 
weight of 66 kDa). Tris buffer (0.2 M Tris, 10 mM CaCl2, pH 8.0) was added to dilute the urea 
concentration to 2 M. Each sample was incubated with bovine TPCK-heated trypsin at 50 : 1 
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substrate : enzyme mass ratio for 24 h at 37 ºC. Digested samples were desalted with an HLB 
cartridge (Waters; Milford, MA, USA) and dried by centrifugal evaporation. Each sample was 
labeled with an iTRAQ reagent following the manufacturer’s protocol (Applied Biosystems; 
Foster City, CA, USA) with slight modifications. Briefly, each iTRAQ reagent was solubilized 
with 70 µL ethanol and transferred to peptide mixtures. After 1.5 h of incubation, the reaction 
was quenched by adding 50 µL of water. Labeled samples were mixed in 1 : 1 : 1 : 1 ratios for 
iTRAQ reagents that generate reporter ions m/z 114 : 115 : 116 : 117, respectively. 
 
2.2.4 Offline SCX Fractionation  
For strong-cation exchange (SCX) liquid chromatography the separation was carried out 
on a Polysulfoethyl A 100 mm × 2.1 mm, 5 µm, 200 Å column (The Nest Group Inc,; 
Southborough, MA, USA) with buffers as follows: mobile phase A, 5 mM monopotassium 
phosphate (25% v/v acetonitrile, pH 3.0), and mobile phase B, 5 mM monopotassium phosphate 
and 350 mM potassium chloride (25% v/v acetonitrile, pH 3.0). Dried iTRAQ-labeled samples 
were resuspended in 300 µL of mobile phase A and injected onto the SCX column. The gradient 
for SCX was 0-3 min, 0% B; 3-45 min, 0-75% B; 45-50 min, 75-100% B; 50-55 min, 100% B; 
55-56 min, 100-0% B; and 56-106 min, 0% B. Thirteen SCX fractions were collected and each 
fraction was desalted with an HLB cartridge. 
 
2.2.5 LC-MS/MS Analysis 
Online desalting and reversed phase chromatography was performed with a Nano 2D-LC 
system equipped with an autosampler (Eksigent; Dublin, CA, USA). Mobile phase A and B for 
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these analyses were 3% (v/v) acetonitrile with 0.1% formic acid and 100% (v/v) acetonitrile with 
0.1% formic acid, respectively. SCX fractions were solubilized in 50 µL of H2O with 0.1% 
formic acid and filtered with a 0.45 µm filter (Thermo Fisher Scientific; Waltham, MA, USA). 
For each run, 5 µL of sample was loaded onto a trapping column (100 µm i.d. × 2 cm), which 
was packed in-house with C18 200 Å stationary phase material (Michrom Bioresource Inc.; 
Auburn, CA, USA) at 3 µL/min in 3% mobile phase B for 3 min. After desalting, the sample was 
loaded onto the analytical column (75 µm i.d. × 13.2 cm), which was packed in-house with C18 
100 Å stationary phase material (Michrom Bioresource Inc.; Auburn, CA, USA). Data-
dependent acquisition parameters were as follows: the MS survey scan in the Orbitrap was 
60,000 resolution over 300-800 m/z; CID was performed in the ion trap with normalized 
collision energy 35%; HCD was recorded in the Orbitrap with normalized collision energy 45% 
and 7,500 resolution; the top six most intense ions in the parent MS scan were selected and 
activated using CID and HCD115; dynamic exclusion was enabled with a repeat count of two for 
a duration of 60 sec; a minimum of 5000 ion counts were necessary for fragmentation events. 
Each fraction was subject to triplicate LC-MS/MS. 
 
2.2.6 Database Searching  
.RAW files were analyzed with Proteome Discoverer 1.2 software (Thermo Scientific; 
Waltham, MA, USA). Both CID and HCD spectra were used to obtain sequence information 
against the UniProt human database (04/25/2010, 20295 sequences). Sequest search parameters 
were as follows: enzyme specificity was trypsin with two maximum miscleavages: precursor 
mass tolerance was 10 ppm; fragment mass tolerance was 0.8 Da; N-terminus and lysine 
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modification with iTRAQ (144.102 Da) and cysteine carbamidomethylation (57.021 Da) were 
set as fixed modifications; tyrosine modification with iTRAQ was set as a dynamic modification. 
Decoy database searching was employed to generate medium (p < 0.05) and high (p < 0.01) 
confidence peptide lists. All peptides with medium and high confidence were pooled into a 
single data file and used for final protein identification and quantitation. Proteins with at least 
two spectral counts in a workflow replicate were included for identification. Only proteins with 
at least two spectral counts in a technical replicate were considered for quantitative and statistical 
analysis.  
 
2.2.7 Protein Quantification and Statistical Analysis  
Peptide ratios (e.g., 115/114, 116/114, and 117/114) were calculated based on peak 
intensity of each reporter ion. The protein ratios were the median ratio of the corresponding 
peptide ratios. Coefficient of variance (CV) values were calculated for ratios of proteins 
quantified in at least two workflow replicates. The mean CV value across workflow replicates 
was calculated and used as the total biological variation, Sb. The technical variation, St, was 
calculated for proteins quantified in at least two LC-MS/MS analyses within an individual 
workflow. The relation between the fold-change (F), random variation (S), biological replicates 
per group (n), and technical replicates (m) has been previously reported151 and is expressed by 
the formula 
𝑛 = 2 (𝑍+𝑇)2𝑆2(𝐹−1)2                   (eq 2.1) 
𝑆2 = 𝑆𝑏2
𝑛
+ 𝑆𝑡2
𝑛𝑚
                  (eq 2.2) 
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The quantities Z and T depend on the power of the test and the significance level, respectively. 
The power and significance levels were set as 0.8 and 0.05, respectively, such that the formula 
approximates to  
𝑛 =  20𝑆2(𝐹−1)2                     (eq 2.3) 
𝐹 =  4.47𝑆
𝑛1/2 + 1                 (eq 2.4) 
One-way ANOVA analysis (p < 0.05) was performed for proteins quantified in at least two 
workflow replicates utilizing Microsoft Excel. 
 
2.3 RESULTS AND DISCUSSION 
A robust quantitative shotgun proteomics workflow (Figure 2.1a) was assessed for its 
ability to identify new human plasma proteins and to guide future experimental designs. The 
workflow uses TMD, iTRAQ 4-plex reagents, SCX fractionation, and nanoflow LC-MS/MS on a 
LTQ-Orbitrap Velos MS. The entire workflow was repeated three times using new aliquots of 
four plasma samples that were subject to TMD using a Hu 6 MARS column. The time it takes to 
complete a single workflow replicate is ~ 7 days with a majority of the costs being attributed to 
the MARS column ($5493 and ~ 200 analyses per column) and the iTRAQ reagents ($1390 and 
five analyses per kit). Immunodepletion of samples is very reproducible for single-stage MD 
(Figure 2.1b) and TMD (Figure 2.1c). It is apparent from the chromatograms (Figures 2.1b and 
c) that high-abundance proteins (i.e., tr ~ 12.5 min) are substantially depleted after the TMD step. 
The average % depletion of the six high-abundance proteins is 88% and 92% for MD and TMD, 
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respectively (Supplemental Table S2.1) and is similar to that obtained using other tandem 
depletion strategies. It should be noted that albumin was still detectable after TMD; however 
other abundant proteins (i.e., α-1-antitrypsin, IgG, IgA, transferrin, and haptoglobin) did not have 
any observed peptide hits. The most abundant protein detected based on spectral counts (SCs) 
was complement C3 which had an average total SCs of > 4000 across the workflow replicates. 
The use of a single column to perform dual immunodepletion minimizes the expenses associated 
with the use of multiple MARS or other depletion columns.  
TMD samples were used for further iTRAQ tagging reactions and analyzed with SCX 
LC-MS/MS (Figure 2.1a). A total of 689 unique proteins were identified from the combined 
results of the three independent workflow experiments (Supplemental Table S2.2) and are 
slightly larger than the number of proteins observed in other reports133,137,146,152. The proteins 
identified in this study were compared to the recently release 2011 HPPP plasma protein 
database to assess the depth of proteome coverage. Based on comparisons of identified proteins 
to the 1929 nonredundant sequences reported in HPPP, 399 novel proteins with ≥ 2 SC are 
uniquely observed in these studies (Figure 2.2a). Although the incorporation of a dual depletion 
step and SCX fractionation increases experimental sample preparation time, our results support 
the necessity of these (or similar) steps for identification of commonly detected and novel plasma 
proteins. Due to different experimental designs, LC-MS/MS data acquisition settings, and 
searching engines, the number of identified proteins may vary a lot across laboratoies. It is also 
possible that a portion of the identification is a result of profiles specific to the sample employed. 
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Figure 2.1. Quantitative proteomics workflow for human plasma. a) the iTRAQ-based quantitative 
platform used for plasma proteome analysis in which the flow-through fractions from four crude plasma 
samples (A-D) are modified with iTRAQ 4-plex reagents, pooled into a single mixture, and separated 
with offline SCX-LC-MS/MS. Example chromatograms (λ280nm) from three independent injections of 
plasma sample C upon b) MD and c) TMD are shown. 
 
a)
b) c)
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Proteins identified are provided in Supplemental Table S2.2. A total of 207 proteins were 
observed in all three of the workflow experiments, and more than half of the total proteins were 
observed in a single workflow replicate (Figure 2.2b). With more stringent criteria (i.e., not less 
than 2 unique peptides for protein identification), 209 proteins were identified across three 
workflow replicates, and 40 new proteins were identified in these studies in comparison to HPPP 
database. 
 The datasets collected from this TMD strategy were used to examine the variation in the 
entire workflow. iTRAQ reporter ion (i.e., m/z 115, 116, 117) ratios were calculated with respect 
to m/z 114 for each protein. Proteins quantified by at least two SCs were used in the assessment 
of variation. Of the 207 proteins identified in all three workflow replicates, 139 proteins (with at 
least two SC) were quantified in the Proteome Discoverer analysis. These proteins were used to 
initially assess the variance in reporter ion ratios across the workflow replicates (of which each 
includes three technical replicates) by employing well-established statistical approaches151,153-156. 
We refer to a technical replicate as the cumulative results obtained across individual LC-MS/MS 
analysis of the 13 SCX fractions. Thus within a single workflow experiment three technical 
replicates were measured. The workflow replicate assesses the variation beginning with the start 
of the plasma sample preparation. 
Figure 2.3a plots the distribution of CV values for proteins as a function of reporter ion 
ratios (e.g., 115/114, 116/114, and 117/114). The distribution of SD values for proteins as a 
function of log2 transformed ratios are provided in Supplemental Figure S2.1. Within a single 
workflow replicate, the average reporter ion ratio across technical replicates was calculated for  
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Figure 2.2. Venn diagram for proteins identified using the TMD workflow. a) Venn diagram for proteins 
identified in the human plasma proteome project (HPPP) and the TMD workflow presented herein. b) 
Venn diagram for proteins identified in three workflow replicate (WR) experiments.  
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individual proteins. The corresponding mean (and median) CV values for ratios 115/114, 
116/114, and 117/114 across all proteins quantified in the three workflow replicates was ± 0.16 
(0.13), 0.13 (0.11), and 0.11 (0.09), respectively. Seventy-five percent of proteins had a CV < 
0.16, and 90% of proteins had a CV < 0.21 when reporter ion 114 was used as the reference 
channel. Because the reporter ion channel used as the reference can have some effect on 
quantitation, the mean (and median) CV values were also calculated for different reference 
channels (Supplemental Table S2.3). When reporter ions m/z 115, 116, and 117 were used as the 
reference channel, 90% of proteins had a CV value < 0.28, 0.21 and 0.24, respectively. This 
range of CV values that results from selection of different reference channels reflects the 
variation inherent in the four plasma samples as well as any variation that arises during LC-
MS/MS analysis. 
 Incorporation of multiple workflow or technical replicates does not imply that proteins 
will be observed in all experiments (Figure 2.2b); therefore CV values were also calculated for 
the 71 proteins that were only quantified in any two of the three workflow replicates. When 
reporter ion m/z 114 was used as the reference channel, the mean (and median) CV was ± 0.30 
(0.23), 0.20 (0.15), and 0.18 (0.15) for ratios 115/114, 116/114, and 117/114, respectively 
(Supplemental Table S2.3). The higher CV observed for this set of proteins agrees with the 
notion that less replication (workflow and technical) could lead to higher variation in reporter ion 
ratios147,153 as well as biases that arise in low-abundance proteins due to lower numbers of 
detected SCs and higher variability due to lower intensity signals149. Higher variability in 
reporter ion ratios correlated with proteins that were identified with lower numbers of SCs 
(Figure 2.3b). 
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 In order to estimate the overall variance of this workflow, CV values were obtained for 
proteins quantified in at least two of the workflow replicates (N = 210). The mean CV was 0.21, 
0.15, and 0.13 for ratios 115/114, 116/114, and 117/114, respectively, and similar values were 
obtained for other reference channels (Supplemental Table S2.3). Taking the CV values of 
reference channels 114 into consideration, the overall variation in the entire plasma workflow is 
~ 0.16. Herein, the technical variation was assessed by considering proteins observed in multiple 
LC-MS/MS analyses for individual workflow replicates. The technical variation is ~ 0.10 for 
proteins quantified in at least two replicates (Supplemental Table S2.4). In order to determine 
proteins that were quantified similarly across workflow replicates, one-way ANOVA analysis (p 
< 0.05) was carried out. Based on these results, ~ 70 of the 210 quantified proteins have similar 
ratios across workflow replicates. 
 Power analysis was also performed in order to assess the fold-change criterion that 
should be applied based on a given number of biological replicates (Figure 2.3c). We note that 
our experimental approach (i.e., repeating the workflow using new aliquots of the same plasma 
samples) does not represent a true biological replicate. However, this analysis still provides 
statistical insight to the power of biological replication in future experimental designs. The total 
biological variance (Sb), technical variance (St), power, and significance level applied were 0.16, 
0.10, 80%, and 0.05, respectively. As indicated in Figure 2.3c, if ten biological replicates per 
group are used then a fold-change cutoff of 1.3 can be applied, and only two replicates are 
required to use the commonly applied 2.0 fold-change cutoff. Technical replicates do not appear 
to have a significant effect on the fold-change criterion when multiple biological replicates will 
be used (Figure 2.3c). These data provide additional evidence to support the notion that  
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Figure 2.3. The variation of proteomics workflow for human plasma. a) The distribution of CV values for 
I115/I114 (grey rectangular), I116/I114 (shaded rectangular), and I117/I114 (black rectangular) for proteins 
quantified in each of the three independent experiments (N = 139 proteins). The cumulative frequency of 
proteins with specific CV values for I115/I114 (dashed square), I116/I114 (dashed triangle), and I117/I114 
(dashed circle) are shown. b) Plot of the mean CV values for reporter ion ratios relative to reference 
channel 114 as a function of the number of spectral counts identified for each protein. Only proteins 
identified in all three workflow replicates are represented in this plot. c) Power analysis for iTRAQ-based 
quantitative platform whereby fold-change values are plotted for a given number of biological replicates 
as a function of the number of technical replicates (i.e., m = 1 to 4). The power and significant level 
values were set to 80% and 0.05, respectively. 
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biological replication (i.e., in these studies workflow replication) is one of the most important 
factors that should be considered in the experimental design145,148,151. 
 
2.4 CONCLUSIONS 
 This chapter has presented a robust quantitative plasma proteomics workflow that 
involves tandem MARS depletion, iTRAQ tagging, and SCX-LC/MS/MS analysis. The use of 
TMD and SCX fractionation resulted in the identification of 689 proteins with ≥ two SCs. 
Compared to the HUPO database, ~ 400 of these proteins were previously unreported. The use of 
TMD and SCX fractionation significantly increases the number of proteins detected. The overall 
variation in the presented workflow range from ± 11 to 30%, and power analysis indicates that 
increasing biological replication would allow a lower fold-change cutoff to be applied to 
determine statistically relevant differentially-expressed proteins. Chapter 4 in this dissertation 
involves the application of this workflow to sepsis whereby biological replicates are also being 
incorporated into the experimental design.  
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3.0 MS3-BASED QUANTITATIVE PROTEOMICS USING PULSED-Q DISSOCIATION 
3.1 INTRODUCTION 
 Quantitative proteomics using mass spectrometry (MS) offers several methods to perform 
relative quantitation between multiple samples with stable isotopes101. Precursor isotopic 
labeling employs light and heavy chemical tags to generate peptide pairs or triplets in parent MS 
scans157,158. Such methods include stable isotope labeling by amino acids in cell culture 
(SILAC)159, acetylation160, dimethylation161, isotope-coded affinity tags (ICAT)162, 16O/18O 
labeling163, isotope coded protein labeling164, and neutron encoded labeling105,106,165. A second 
approach uses isobaric tags such as tandem mass tags (TMT)107, isobaric tags for relative and 
absolute quantitation (iTRAQ)102, deuterium isobaric amine-reactive tags (DiART)166, and 
dimethyl leucine tags167. Proteins can be quantified based on the reporter ion signals generated 
from tandem mass spectrometry (MS/MS). Chapter 2 has demonstrated the ability of the 
iTRAQ-based proteomics method to quantify proteins in complex biological samples. Isobaric 
tags can offer multiplexing up to ten samples simultaneously through isotopologues resolved 
with high resolution instruments104-106. Combination of precursor isotopic labeling and isobaric 
tagging results in enhanced multiplexing168-171.  
 A major limitation to the isobaric tagging method is ratio distortion of reporter ions. This 
occurs due to coisolation and cofragmentation of closely spaced peptides within a given isolation 
window144. Gas phase purification172, analysis of TMT complement reporter ion clusters173, and 
triple stage mass spectrometry (MS3)174 can help minimize cofragmentation of neighboring 
peptides and provide accurate reporter ion ratios. MS3 is possible on any hybrid ion trap/Orbitrap 
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MS instrument without the need for hardware or software modifications174. TMT or iTRAQ-
tagged peptide ions are fragmented with collision induced dissociation (CID), from which, the 
most intense fragment ions are isolated and subject to higher energy collision dissociation (HCD) 
in order to detect reporter ions174. HCD-MS3 offers high fragmentation efficiency and 
reproducibility.  Additionally, reporter ion detection using the Orbitrap gives high resolution and 
mass accuracy104,168,170. The duty cycle of HCD-MS3, however, is lower compared to HCD-
MS/MS, which reduces the number of identified and quantified proteins174. Reporter ion 
channels have a higher probability of missing signal due to relatively low sensitivity of the MS3 
acquisition and Orbitrap175. Particularly, the HCD-MS3 method, is only applicable to laboratories 
which have access to high resolution Orbitrap MS instruments.  
 Pulsed-Q dissociation (PQD) is an alternative fragmentation method for reporter ion 
detection on linear ion trap (LTQ) platforms176-178. PQD-MS/MS on the LTQ offers faster scan 
rates and improved sensitivity and provides comparable quantitative accuracy compared to the 
HCD-MS/MS on an Orbitrap176-178. PQD for MS3 data acquisition has not been investigated. 
Herein, we present a new reporter ion quantitation method using PQD-MS3 on an LTQ-Orbitrap 
MS. Recently, our laboratory has shown that selection of y1 ions (e.g., lysine-TMT tagged ion) 
for MS3 data acquisition offers an alternative method to the selection of the most intense 
fragment ion in CID MS/MS spectra168. Therefore, we assessed the performance of top ion and 
y1 ion selection of TMT-labeled peptides using PQD-MS3. Higher numbers of identified and 
quantified proteins and spectral counts are obtained using PQD-MS3 compared to HCD-MS3. 
PQD-MS3 methods provide accurate reporter ion ratios comparable to HCD-MS3. Finally, we 
demonstrate accurate reporter ion quantitation with PQD-MS3 on an LTQ instrument. 
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3.2 EXPERIMENTAL AND MATERIALS 
3.2.1 Mouse Brain Samples 
 Wild-type (WT) male mice (14 months old, C57BL/6J) were purchased from Jackson 
Laboratory and housed in the Division of Laboratory Animal Resources at the University of 
Pittsburgh. Mice were fed standard Purina rodent laboratory chow ad libitum on a 12 h light/dark 
cycle. All animal protocols were approved by the Institutional Animal Care and Use Committee 
at the University of Pittsburgh. Brain tissue was harvested from one such mouse. 
  
3.2.2 Brain Protein Extraction and Digestion 
 Brains were homogenized in PBS buffer with 8 M urea, centrifuged at 13,000 rpm, and 
the protein concentration of the supernatant was determined by BCA assay. Proteins (200 µg) 
were reduced with 1 : 40 molar excess of dithiothreitol for 2 h at 37 °C, and then alkylated with 1 
: 80 molar excess of iodoacetamide for 2 h on ice in the dark. The alkylation reaction was 
quenched by adding 1 : 40 molar excess of cysteine, and the mixture was incubated at room 
temperature for 30 min. Tris buffer (0.2 M Tris, 10 mM CaCl2, pH 8.0) was added to dilute the 
urea concentration to 2 M. Proteins were digested with  trypsin at 1 : 50 protein : enzyme for 24 
h at 37 °C. Protein digests were split into four aliquots with the ratio 1 : 1 : 2 : 5 (10µg : 10µg : 
20µg : 50µg) and labeled with TMT-128, 129, 130, and 131 reagents, respectively, according to 
the manufacturer’s protocol (Thermo Fisher Scientific; Waltham, MA, USA). After TMT-
labeling, four samples were combined, cleaned up with HLB cartridge (Waters; Milford, MA, 
USA), and dried with SpeedVac.  
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3.2.3 LC-MS3 Acquisition 
 The combined mixture was separated using nanoflow reversed phase liquid 
chromatography (nRPLC)168 and eluted peptides were nanosprayed into an LTQ-Orbitrap Velos 
instrument. Triplicate injections were performed. Data-dependent acquisition parameters were as 
follows: parent scan range 300-1800 m/z, 60,000 resolution, automated gain control (AGC) 
1x106.  To keep the cycle time between HCD-MS3 and PQD-MS3 similar (~ 2.4 s), the top four 
or top seven ions from parent MS scans were selected for CID [35% normalized collision energy 
(NCE), 2.0 isolation window, and 10 ms activation time] followed by either HCD-MS3 (4.0 
isolation window, 60% NCE, activation time 0.1 ms, and AGC 3×105) or PQD-MS3 (4.0 
isolation window, 33% NCE, activation Q 0.5, activation time 0.1 ms, and AGC 7×104), 
respectively. PQD-MS3 was also applied on a LTQ-Orbitrap Velos using the dual ion trap only 
and a stand-alone LTQ as follows: parent scan range 300-1800 m/z and AGC 3x104. The top 
seven ions from parent MS scans were selected for CID (35% NCE, 2.0 isolation window, 10 ms 
and 30 ms activation time for LTQ Velos and LTQ data acquisition, respectively) followed by 
PQD-MS3 (LTQ Velos data acquisition: 4.0 isolation window, 33% NCE, activation Q 0.5, 
activation time 0.1 ms, AGC 7×104; LTQ data acquisition: 4.0 isolation window, 27% NCE, 
activation Q 0.7, activation time 0.1 ms, AGC 1.5×105). The most intense CID fragment ion 
within the range 300-800 m/z (termed as HCD-MS3-top ion or PQD-MS3-top ion) or the CID y1 
fragment ion (m/z 376.3; termed as HCD-MS3-y1 or PQD-MS3-y1) was selected for MS3. 
Dynamic exclusion was disabled in order to increase the probability of acquiring MS3 spectra 
without missing reporter ion values.   
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3.2.4 Data Analysis 
 .RAW files were searched against the International Protein Index (IPI) mouse proteome 
database (v3.87, 59534 sequences, 08/16/2012) using SEQUEST with the following parameters: 
trypsin with two miscleavages, 15 ppm and 1 Da parent mass tolerance for LTQ-Orbitrap and 
LTQ platform analysis, respectively, 1 Da fragment mass tolerance, static modifications of TMT 
tags (229.163 Da) on the N-termini and lysine residues, carbamidomethyl (57.021 Da) on 
cysteine, dynamic modification of oxidation (15.995 Da) on methionine. Decoy database 
searching was enabled using a reverse protein database with false discovery rates set at 0.01 and 
0.05 for high and medium confidence peptides, respectively. Search results were processed and 
reporter ion intensities were extracted (centroid with smallest delta mass, 20 ppm and 0.4 Da 
integration tolerances for HCD-MS3 and PQD-MS3, respectively) using Proteome Discoverer 
v1.4 (Thermo Scientific; Waltham, MA, USA).   
 
3.3 RESULTS AND DISCUSSION 
The workflow for this study is shown in Figure 3.1. Mouse brain proteins were digested 
with trypsin, split into four aliquots with the ratio 1 : 1 : 2 : 5, labeled with TMT-128, 129, 130, 
131 reagents, respectively. After labeling, the four aliquots were pooled as one single mixture 
and analyzed by different methods (Figure 3.1). Trypsin was selected as the protease because it 
gives more identified and quantified peptides and proteins for HCD-MS3 168,175.  Direct infusion 
experiments using TMT-labeled angiotensin II were performed to calculate the time required for 
HCD-MS3 and PQD-MS3 top ion methods (data not shown).  It was determined that MS3 
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fragmentation of the top four and seven ions for HCD-MS3 and PQD-MS3, respectively, resulted 
in similar instrument cycle times between each parent scan (~ 2.4 s). Figures 3.2a, b, d, and f 
demonstrate an example peptide quantified with HCD-MS3-top ion and PQD-MS3-top ion. The 
peak at m/z 683.4247 in the parent scan (Figure 3.2a) has been identified as the peptide 
N(TMT6)LLSVAYK(TMT6) from CID MS/MS data (Figure 3.2b). This peptide corresponds to 
protein 14-3-3β protein. The y5 ion (m/z 796.65) was isolated and fragmented in HCD- (Figure 
3.2d) and PQD-MS3-top ion (Figure 3.2f), respectively. Reporter ion ratios of 1.0 : 1.1 : 2.5 : 5.6 
and 1.0 : 1.0 : 2.3 : 5.4 were obtained from HCD- and PQD-MS3-top ion, respectively (inserts of 
Figure 3.2d and f).  Box plots of ratios for all TMT-tagged proteins are shown in Figure 3.3a for 
HCD- and PQD-MS3-top ion.  Calculated protein ratios obtained in HCD-MS3-top ion and PQD-
MS3-top ion were 1.0 ± 0.1, 2.0 ± 0.3, 5.6 ± 0.8 (N = 113, average ± standard deviation) and 1.2 
± 0.6, 2.3 ± 1.5, 5.4 ± 3.8 (N=156, average ± standard deviation), respectively. The PQD-MS3-
top ion method provides accurate protein ratios similar to HCD-MS3. However, lower precision 
of reporter ion ratios was observed using PQD-MS3-top ion (Figure 3.3). This can be attributed 
to lower reproducibility and inefficiency of PQD fragmentation compared to HCD176-178.  For 
example, the y5 ion is the base peak in MS3 spectra from PQD-MS3-top ion (Figure 3.2f) 
indicating low fragmentation efficiency. 
A complete list of identified proteins (Supplemental Table S3.1) and peptides 
(Supplemental Table S3.2) is provided.  There is an apparent increase in the total number of 
identified and quantified proteins and peptides when comparing PQD-MS3-top ion with HCD-
MS3-top ion.  The number of identified spectral counts [(SCs), (total proteins)] was 9897 (135) 
and 16502  (186) for HCD- and PQD-MS3-top ion, respectively (Table 3.1).  We attribute this 
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increase to the faster scan rates of the LTQ (PQD-MS3-top ion)179. The LTQ performs more CID 
MS/MS and PQD-MS3 scans in the same amount of time compared to Orbitrap HCD-MS3 (i.e., 
50360 vs 30374).  This resulted in an increased number of quantified SCs (proteins) from 7473 
(113) for HCD-MS3-top ion to 9776 (156) for PQD-MS3-top ion (Table 3.1).   
Recently, we reported a global combined precursor isotopic labeling and isobaric tagging 
(cPILOT), which incorporates selective HCD-MS3 acquisition168. The selective MS3 isolates the 
y1 CID fragment arising from C-terminal lysine-TMT tagged peptides and increases MS3 spectra 
containing a reporter ion168.  Herein, the performance of HCD-MS3-y1 and PQD-MS3-y1 was also 
assessed. Figure 3.2 shows a sample spectra for the peptide N(TMT6)LLSVAYK(TMT6).  
Selection of the y1 fragment ion for HCD-MS3 and PQD-MS3 (Figures 3.2c and e, respectively) 
results in reporter ion ratios of 1.0 : 1.1 : 2.2 : 5.7 and 1.0 : 1.0 : 2.0 : 5.6.   
Measured log2 protein ratios are 1.0 ± 0.2, 2.0 ± 0.7, 5.3 ± 0.9 (N = 114, average ± 
standard deviation) and 1.2 ± 1.1, 2.5 ± 1.5, 6.4 ± 3.8 (N = 199, average ± standard deviation) for 
HCD-MS3-y1 and PQD-MS3-y1, respectively (Figure 3.3b). The number of identified and 
quantified proteins increased by 26% (from 180 to 226) and 75% (from 114 to 200), respectively 
in PQD-MS3-y1 compared with those in PQD-MS3-y1 (Table 3.1). Similarly, this increase can be 
due to the faster scan rate of the LTQ.   
Consistent with our previous reports168, HCD- and PQD-MS3-y1 increased the number of 
identified SCs and proteins compared to the corresponding top ion methods (Table 3.1). 
Quantified SCs and proteins also increased in PQD-MS3-y1 in comparison to PQD-MS3-top ion, 
whereas quantified spectral counts decreased in HCD-MS3-y1 compared to HCD-MS3-top ion 
(no significant difference in the number of quantified proteins) (Table 3.1). This may be   
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Figure 3.1. Schematic diagram of the proteomics workflow involving mouse brain protein digestion, 
TMT tags labeling and mass spectrometry analysis with different instrument methods. 
 
protein extraction
trypsin digestion
TMT 128 TMT 129 TMT 130 TMT 131
10µg
1 1 2 5 ： ： ：
HCD-MS3-top ion HCD-MS3-y1PQD-MS3-top ion PQD-MS3-y1
20µg 50µg10µg
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Figure 3.2. Example of HCD- and PQD-MS3 results. a) MS spectrum for the peptide 
N(TMT6)LLSVAYK(TMT6), and b) the corresponding CID MS2 spectrum for the peptide identification. 
The shaded region corresponds to the m/z range (300-800) for the selection of the most intense ion for 
N(TMT6)   L  L S  V  A  Y  K(TMT6)
b2b1 b3 b4 b5 b6 b7
y1y2y3y4y5y6y7
MS
CID MS2
MS3
y1 ion top ion
HCD-MS3-y1 HCD-MS3-top ion
PQD-MS3-y1 PQD-MS3-top ion
a)
b)
c) d)
e) f) 796.85
376.27
131.14
130.14
129.13128.13
131.14
130.14
129.13128.13
376.37131.23
130.17
129.07128.14
376.37
131.23
130.17
129.07128.14
683.4247
684.4278
684.9291
683.9263
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MS3. The (**) indicates the most intense ion selected for MS3 in d) HCD-MS3-top ion and f) PQD-MS3-
top ion. The (*) indicates the y1 ion selected for MS3 in c) HCD-MS3-y1 ion and e) PQD-MS3-y1 ion. 
Inserts in c-f) are the corresponding reporter ion intensity. 
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Figure 3.3. Box plots of measured log2 protein reporter ion ratios using a) HCD-MS3 top ion and PQD-
MS3-top ion and b) HCD-MS3-y1 and PQD-MS3-y1.  Theoretical ratios are 1 : 1, 2 : 1, and 5 : 1.  
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Table 3.1. Number of spectral counts and proteins identified and quantified in 
each MS3 method. 
 
Identification Quantitation 
 
Spectral counts Protein Spectral counts Protein 
HCD-MS3-top ion 9897 135 7473 113 
PQD-MS3-top ion 16502 186 9776 156 
HCD-MS3-y1 13090 180 3530 114 
PQD-MS3-y1 17392 226 11843 200 
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explained by the relatively low intensity of y1 ion and low sensitivity of the Orbitrap. Our data 
shows that the intensity of y1 ion is ~ 40% of the base peak in CID MS/MS. Selection of the y1 
ion results in lower signal of reporter ions in MS3 spectra compared to the top ion method. The 
low signal can be detectable in the LTQ which has higher sensitivity but not in the Orbitrap. It 
should be noted that in our previous cPILOT report168, the tagging chemistry was designed so 
that b-ions did not contain a TMT tag due to the N-termini being capped with a dimethyl group.  
The presented experiments show that accurate reporter ion quantitation can be obtained using 
PQD-MS3-top ion and PQD-MS3-y1 methods. Additionally, selective PQD-MS3-y1 data 
collection results in increased protein and peptide identification and quantitation.   
Finally, PQD-MS3 was applied on two other mass spectrometer instruments: LTQ Velos 
and LTQ.  We note that the LTQ Velos experiment was performed on the LTQ-Orbitrap Velos 
hybrid by performing all scan events using the dual linear ion trap.  Using the LTQ Velos, PQD-
MS3-top ion and PQD-MS3-y1 resulted in accurate quantitation as 1.3 ± 0.9, 2.2 ± 1.2, 4.2 ± 2.8 
(N = 84, average ± standard deviation) and 1.2 ± 0.9, 2.1 ± 1.2, 4.9 ± 2.6 (N = 119, average ± 
standard deviation), respectively (Figure 3.4).  As described above, the number of identified and 
quantified proteins and peptides increases with the PQD-MS3-y1 method (data not shown). 
Similar experiments were performed on the LTQ, however only the PQD-MS3-top ion resulted in 
reporter ion signal in MS3.  PQD-MS3-y1 using the LTQ did not result in any reporter ion signal 
in MS3 spectra, which could be due to low sensitivity in the LTQ compared to the LTQ Velos 180.  
When performing PQD-MS3 experiments on an LTQ, we suggest to only use the top ion 
selection method. Lower number of identified and quantified proteins and peptides were also 
obtained using PQD-MS3 on the stand-alone LTQ, which may be caused by the relatively slower  
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Figure 3.4. Box plots of the measured log2 protein ratios performing PQD-MS3-y1 LTQ Velos (N = 119), 
PQD-MS3-top ion-LTQ Velos (N = 84), and PQD-MS3-top ion-LTQ (N = 28).  
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scan rate of the LTQ. However, accurate protein reporter ion results, 1.0 ± 0.7, 1. 9± 1.2, 4.2 
±2 .8 (N = 28, average ± standard deviation), were obtained using PQD-MS3-top ion (Figure 3.4). 
Overall, these experiments show that accurate proteomics quantitation can be obtained on lower 
resolution LTQ instruments. 
 
3.4 CONCLUSIONS 
This study demonstrates that PQD-MS3 quantitation of isobaric tags is a feasible 
proteomics method. PQD-MS3 takes advantage of the high sensitivity and fast scan rate of linear 
ion trap which leads to increased numbers of identified and quantified peptides and proteins.  
Accurate quantitation is achieved using PQD-MS3 and is comparable to previously described 
HCD-MS3 methods.  Selective MS3 fragmentation of the y1 ion from CID spectra using PQD-
MS3 results in an even higher number of proteins and peptides quantitified. The PQD-MS3 
methods can be useful especially for laboratories which do not have access to an Orbitrap 
instrument. 
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4.0 PROTEOMICS REVEALS AGE-RELATED DIFFERENCES IN THE HOST 
IMMUNE RESPONSE TO SEPSIS97* 
(*note that information in this Chapter is written based on a published paper, Cao, Z.; Yende, S.; Kellum, 
J. A.; Angus, D. C.; Robinson, R. A. S. Journal of Proteome Research 2013, 13, 422) 
4.1 INTRODUCTION 
Sepsis is a systemic inflammatory state triggered by infection. The additional diagnosis 
of multiple organ failure and hypoperfusion (e.g., hypotension, decreased urine output) along 
with sepsis results in severe sepsis181. One of the leading causes of sepsis is community-acquired 
pneumonia (CAP)22,48,182. The presence and severity of organ failure is one of the most important 
determinants of mortality following sepsis17,183-187. Severe sepsis affects ~ 750,000 persons 
annually in the United States17,23,184-187 and is one of the most common causes of death in 
intensive care units17,184-187.  
Kellum and coworkers have shown that the incidence of severe sepsis and mortality rate 
increases sharply after the age of 6516,188. For example, CAP patients ≥ 85 years old have a 2.8-
fold increased risk of severe sepsis and a 17-fold increased mortality rate compared to patients ≤ 
50 years old48. The notable age-related differences in severe sepsis risk may be explained in part 
by immunosenescence underlying chronic disease. Immunosenescence is manifested in the 
elderly through decreased numbers of T-cells, impaired B-cell function, increased apoptosis of 
neutrophils, and reduced bactericidal response of macrophages188-190. Most studies that examine 
age-related differences in immune response using animal models and humans have largely 
focused on either the adaptive immune response or select pathways (inflammatory, coagulation, 
and fibrinolysis markers) in the innate immune response189-195. A comprehensive assessment of 
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differences in the immune response has not been conducted. Trials testing immunomodulating 
therapies for sepsis in broad populations have failed to consistently improve outcomes of sepsis 
patients25. An alternative approach is to personalize sepsis therapies based on host 
characteristics, such as age. To further the development of such a personalized approach, a better 
understanding of the differences in immune response due to age is necessary.  
Herein, we conducted a nested case-control study using patients enrolled in an 
observational cohort of CAP. A semi-quantitative plasma proteomics workflow previously 
developed in our laboratory196, which included tandem immunoaffinity depletion, isobaric tags 
for relative and absolute quantitation (iTRAQ) labeling, strong cation exchange (SCX) 
fractionation, and nanoflow liquid chromatography (LC) coupled to high resolution mass 
spectrometry (MS), was applied to patient samples. We analyzed plasma proteins on presentation 
to the emergency department (ED) to compare the acute immune response. First, proteins were 
identified that differed between those who did or did not develop severe sepsis (within 90 days of 
hospitalization) among younger and older adults separately. We hypothesized that there may be 
differentially-expressed proteins that are unique to the younger or older adults which would help 
to explain the increased risk of severe sepsis in older adults. In addition to identifying these sets 
of proteins, differentially-expressed proteins that are common to the younger and older adult 
groups were also identified. Interestingly, the direction of fold-change observed for these 
common proteins varies depending on patient age and thus may explain higher risk of severe 
sepsis in older adults.  These results and the implications of this study are presented herein. 
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4.2 EXPERIMENTAL AND MATERIALS 
4.2.1 Ethics Statement  
The Institutional Review Boards at the following hospitals approved the study: 
Pennsylvania: Allegheny General Hospital, Jefferson Hospital/SHHS, Mercy Hospital, St. Clair 
Memorial Hospital, St. Francis Medical Center, Sewickley Valley Hospital, University of 
Pittsburgh Medical Center (UPMC) Braddock, UPMC Horizon, UPMC Lee, UPMC 
McKeesport, UPMC Passavant, UPMC Presbyterian, UPMC Shadyside, UPMC Southside, 
UPMC St. Margaret, West Penn Hospital; Connecticut: Bridgeport Hospital, Hartford Hospital, 
Milford Hospital, New Britain General Hospital, Norwalk Hospital, Yale-New Haven Hospital; 
Tennessee: Methodist Health Care (single IRB approval for three Methodist University sites); 
Michigan: Henry Ford Health System, Detroit Receving/Sinai-Grace, Wayne State. Written, 
informed consent was obtained from all participants or by proxy. 
 
4.2.2 Study Design and Patients  
We conducted a nested case-control study using patients enrolled in the GenIMS study150. 
GenIMS is a prospective multicenter observational cohort of patients with CAP enrolled in EDs 
of 28 academic and community hospitals in four US regions, including southwestern 
Pennsylvania, Connecticut, southern Michigan and western Tennessee. Details of this study 
including eligibility criteria have been described previously48,150. 
To compare differences in immune response across different age groups and between 
patients with and without severe sepsis, we identified a total of 39 patients from four groups. 
These included: 1) patients 50-65 years old who did not develop severe (hereafter referred to as 
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young controls [YC]), 2) patients 70-85 years old who did not develop severe sepsis (hereafter 
referred to as old controls [OC]), 3) patients 50-65 years old who developed severe sepsis within 
90 days after presentation to the ED (hereafter referred to as young severe sepsis [YS]), and 4) 
patients 70-85 years old who developed severe sepsis within 90 days after presentation to the ED 
(hereafter referred to as old severe sepsis [OS]). To ensure that differences in immune response 
are attributed to age and not to ethnic differences or underlying chronic diseases, only whites and 
matched patients according to chronic disease burden were included (Table 4.1).  
 
4.2.3 Plasma Samples and Tandem MARS Depletion  
Plasma samples were obtained on day 1 when CAP patients were admitted to the ED and 
prior to most interventions to ensure that differences in immune response are not affected by 
therapeutic strategies. Negative results were obtained in the blood culture test used to identify the 
pathogenic source of the samples obtained from CAP patients. The Hu-6 MARS column 
(Agilent; Santa Clara, CA, USA) depletes serum albumin, IgG, α1-antitrypsin, IgA, transferrin, 
and haptoglobin proteins.  An injection amount of 60 μL of crude plasma was applied to the 
MARS column and after the initial depletion flow-through fractions were concentrated with a 5K 
molecular weight cutoff concentrator (Agilent; Santa Clara, CA, USA) at 4695 g at 4 °C for 1.5 
h. Samples were then stored at -80 °C or re-injected onto the MARS column for tandem MARS 
depletion.  The second flow-through fractions (hereafter referred to as TMD) were concentrated 
and protein concentrations were measured using the BCA protein assay.   
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Table 4.1. Characteristics of the subjects used in the studies. 
 
 
YS a YC b OS c OC d
Number of subjects in group 9 10 10 10
Mean age 58.33 57.20 81.50 79.30
Stdev e age (+/-) 5.45 4.57 3.21 3.13
Age Range 52-65 52-66 75-85 75-86
# Male patients 4 6 6 1
# Race = white 9 10 10 10
Risk of developing severe sepsis 9 0 10 0
# Patients with SS f  upon the presence of ED g 6 0 8 0
# Patients developing SS in future 3 0 2 0
# Smokers 7 6 8 4
# Patients with respiratory disease 0 0 0 0
# Patients with renal disease 0 0 0 0
# Patients with cardiac disease 0 0 0 0
# Patients with neoplastic disease 0 0 0 0
# Patients with charlson > 0 0 0 0 0
a subjects who are at the age of 50-65 and with severe sepsis;
b subjects who are at the age of 50-65 and without severe sepsis;
c subjects who are at the age of 70-85 and with severe sepsis;
d subjects who are at the age of 70-85 and without severe sepsis;
e standard deviation
f severe sepsis.
g emergency department.
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4.2.4 Protein Digestion  
Protein was denatured with an extraction buffer (0.2 M Tris, 8 M urea, 10 mM CaCl2, pH 
8.0), reduced with 1 : 40 molar excess of dithiothreitol (DTT) for 2 h at 37 °C, and then alkylated 
with 1 : 80 molar excess of iodoacetamide (IAM) for 2 h on ice. The alkylation reaction was 
quenched by adding 1 : 40 molar excess of Cysteine and the mixture was incubated at room 
temperature for 30 min. Tris buffer (0.2 M Tris, 10 mM CaCl2, pH 8.0) was added to dilute the 
urea concentration to 2 M. Each sample was incubated with bovine TPCK-heated trypsin at 1 : 
50 substrate :  enzyme ratio for 24 h at 37 ºC.  
 
4.2.5 iTRAQ Labeling  
Digested samples were desalted with an HLB cartridge (Waters; Milford, MA, USA) and 
dried by centrifugal evaporation. Each sample was labeled with an iTRAQ reagent following the 
manufacturer’s protocol (Applied Biosystems; Foster City, CA, USA) with slight modifications. 
Briefly, each iTRAQ reagent was solubilized with 70 μL ethanol and transferred to peptide 
mixtures. After 1.5 h of incubation, the reaction was quenched with water. Labeled samples were 
mixed in 1 : 1 : 1 : 1 ratios for iTRAQ reagents that generate reporter ions at m/z 114 : 115 : 116 : 
117, respectively.   
 
4.2.6 SCX Fractionation  
SCX fractionation was carried out on a PolySulfoethyl A 100 mm x 2.1 mm, 5 μm, 200 Å 
column (The Nest Group, Inc.; Southborough, MA, USA) with buffers as follows: mobile phase 
A was 5 mM monopotassium phosphate (25% v/v acetonitrile, pH 3.0), and mobile phase B was 
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5 mM monopotassium phosphate, 350 mM potassium chloride, (25% v/v acetonitrile, pH 3.0). 
Dried iTRAQ labeled samples were resuspended in 300 μL of mobile phase A and injected onto 
the SCX column.  The gradient for SCX was: 0-3 min, 0% B; 3-45 min, 0-75% B; 45-50 min, 
75-100% B; 50-55 min, 100% mobile phase B; 55-56 min, 100-0% B; 56-106 min, 0% B. 
Thirteen SCX fractions were collected and each fraction was desalted with an HLB cartridge 
(Waters; Milford, MA, USA).   
 
4.2.7 LC-MS/MS Analysis  
  Online desalting and reversed phase chromatography was performed with a Nano2D-LC 
system equipped with an autosampler (Eksigent; Dublin, CA, USA).  Mobile phase A and B for 
these analyses were 3% (v/v) acetonitrile with 0.1% formic acid and 100% (v/v) acetonitrile with 
0.1% formic acid, respectively. SCX fractions (5 μL) were loaded onto a trapping column (100 
μm i.d. × 2 cm), which was packed in-house with C18 200 Å 3 µm stationary phase material 
(Michrom Bioresource Inc.; Auburn, CA) at 3 μL⋅min-1 in 3% mobile phase B for 3 min. After 
desalting, the sample was loaded onto an analytical column (75 μm i.d. × 13.2 cm), which was 
packed in-house with C18 100 Å 3µm stationary phase material (Michrom Bioresource Inc.; 
Auburn, CA, USA). The gradient was as follows: 0-5 min, 10% mobile phase B; 5-75 min, 10-
30% B; 75-95 min, 30-60% B; 95-100 min, 60-90% B; 100-105 min, 90-10% B; 110-120 min, 
10% B. The LC eluent was analyzed with positive ion nanoflow electrospray using a LTQ-
Orbitrap Velos mass spectrometer (Thermo Scientific, Waltham, MA, USA). Data-dependent 
acquisition parameters were as follows: the MS survey scan in the Orbitrap was 60,000 
resolution over 300-1800 m/z; the top six most intense peaks in the MS survey scan were isolated 
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and fragmented with CID and HCD; CID was performed in the ion trap with normalized 
collision energy 35%; HCD was recorded in the Orbitrap with normalized collision energy 45% 
and 7,500 resolution; dynamic exclusion was enabled and a repeat count of two for a duration of 
60 s was allowed and selected ions were placed on an exclusion list for 61 s. Each SCX fraction 
was subject to triplicate LC-MS/MS analysis.  
 
4.2.8 Data Analysis 
 .RAW files were analyzed with Proteome Discoverer 1.2 software (Thermo Scientific; 
Waltham, MA, USA). Both CID and HCD spectra were used to obtain sequence information 
against the Uniprot human database (04/25/2010, 20295 sequences). Sequest search parameters 
were as follows: two maximum trypsin miscleavages; precursor mass tolerance 10 ppm; 
fragment mass tolerance 0.8 Da; static modifications were iTRAQ-4plex/+144.102 Da (N-
terminus, Lys), and carbamidomethyl modification/+57.021 Da (Cys); dynamic modification of 
iTRAQ-4plex/+144.102 Da (Tyr).  Decoy database searching was employed to generate medium 
(p < 0.05) and high (p < 0.01) confidence peptide lists. Peptides with medium and high 
confidence were used to identify and quantify proteins. The reporter ions (i.e., m/z 114-117) were 
identified with the following parameters: centroid with smallest delta mass, 20 ppm for reporter 
ion mass tolerance. The isotope correction was employed according to the manufacturer’s 
protocol (AB Sciex; Framingham, MA, USA).  Additionally, protein ratios in each experiment 
were normalized based on the protein median ratio option in the software (i.e., individual protein 
value is normalized against the median ratio value obtained across all proteins identified in a 
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given experiment). Only proteins with at least two spectral counts in a technical replicate were 
considered for further analysis. 
 
4.2.9 Statistics  
Coefficient of variation (CV) values were calculated for reporter ion ratios (e.g., 115/114, 
116/114, and 117/114) of proteins quantified in at least six iTRAQ experiments. The mean CV 
value across the iTRAQ experiments was calculated and used as the total biological variation, Sb, 
which was 0.60 in this study. The technical variation, St, was calculated for proteins quantified in 
at least two LC-MS/MS analyses within an individual iTRAQ experiment, which was 0.11 in this 
study.  
From this power analysis, fold-change cutoff was calculated based on equations (eq 2.1-
2.4) shown in Chapter 2 (Section 2.2.7). Stringent filter criteria were applied to generate a list of 
statistically significant differentially-expressed proteins as follows: 1) proteins identified and 
quantified in at least six biological replicates, 2) CV values ≤ 0.60, and 3) fold-change cutoff 
dependent upon n as such  a) ≥ 1.27 or ≤ 0.79 (n=10), b) ≥ 1.28 or ≤ 0.78 (n=9), c) ≥ 1.30 or ≤ 
0.77 (n=8), d) ≥ 1.32 or ≤ 0.76 (n=7), e) ≥ 1.35 or ≤ 0.74 (n=6).   
 
4.2.10 Western Blotting Analysis 
 The changes in the expression of C-reactive protein (CRP), apolipoprotein CIII 
(ApoCIII), and fibrinogen alpha chain (FAC) were subject to Western blotting analysis. Twenty 
µg of TMD proteins was denatured in an appropriate sample buffer and electrophoretically 
separated on a Criterion precast gel (Biorad Laboratories; Hercules, CA, USA) at 140 V. 
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Proteins from the gel were transferred onto a nitrocellulose membrane paper using a Fast-
Transfer Blot System (Biorad; Hercules, CA, USA). Blots were washed three times in Wash blot. 
BSA blocking solution (3%) was added to the membrane and incubated on a rocker for 2 h. A 1 : 
5000 dilution of mouse monoclonal anti-CRP primary antibody (Sigma Aldrich; St. Louis, MO, 
USA), 1 : 5000 dilution of rabbit polyclonal anti-ApoCIII primary antibody (Abcam; Cambridge, 
MA, USA), or 1 : 2500 dilution of rabbit monoclonal anti-FAC primary antibody (Abcam; 
Cambridge, MA, USA) was added and incubated at 4 ºC overnight. The blot was rinsed and 
incubated with a 1 : 7500 dilution of anti-mouse or anti-rabbit IgG alkaline phosphatase 
secondary antibody (Sigma Aldrich; St. Louis, MO, USA) for 1 h on a rocker. The blot was 
rinsed and colorometrically developed using 0.51 mM 5-bromo-4-chloro-3'-indolyphosphate p-
toluidine salt (BCIP) and 0.24 mM nitrotetrazolium blue (NBT). The dried blot was scanned 
using a Canon scanner, saved as a .TIFF file, and densitometry analyses carried out with Scion 
Image Software.  Within each experiment, the intensity for the sample from each group was 
normalized to the total blot intensity and used to generate mean and standard deviation values. 
 
4.2.11 Ingenuity Pathway Analysis  
Differentially-expressed proteins were analyzed using Ingenuity Pathway Analysis (IPA, 
www.ingenuity.com) to generate a list of pathways that are statistically relevant (p < 0.05). 
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4.3 RESULTS 
4.3.1 Data Characterization and Statistical Analysis  
An iTRAQ-based semi-quantitative proteomics workflow196 was employed to identify 
differentially-expressed proteins in 50-65 and 70-85 year old CAP patients who developed 
severe sepsis compared to those patients that did not (Table 4.2). The workflow employs TMD 
on a MARS Hu-6 column to effectively remove high-abundance proteins and allows deeper 
probing into the plasma proteome196. Patient samples from the four groups (i.e., YC, YS, OC and 
OS) were randomly assigned to iTRAQ reagents in a blind fashion across ten SCX-LC-MS/MS 
experiments (Table 4.2). 
 Figure 4.1a shows an example of LC chromatograms for 13 SCX fractions of pooled 
iTRAQ 4-plex samples. The triplicate LC-MS/MS runs for each fraction are reproducible. 
Figures 4.1b-g show example spectra for peaks isolated and fragmented. Doubly-charged 
peptides at m/z 748.9046 (Figure 4.1b) and 742.9010 (Figure 4.1c) in SCX fractions seven and 
six were eluted from the column at tr 57.20 min and 37.26 min, respectively. The CID MS/MS 
spectra (Figures 4.1d and e) display a consecutive series of b- and y-fragment ions used to assign 
the peptides as [YYTYLIMNK+2H]2+ of protein Complement C3 and 
[GWVTDGFSSLK+2H]2+of protein ApoCIII, respectively. A mass increase of 145 Da was 
observed for b1 and y1 ions for each of the two peptides, indicating iTRAQ labeling at the N-
terminus and the presence of lysine at the C-terminus.  HCD MS/MS spectra (Figures 4.1f and g) 
also contain series of b- and y- ions used to confirm the sequence of peptides. The lower m/z 
region of the HCD MS/MS spectra (inserts in Figure 4.1f and g) shows the intensity of the 
reporter ions which is used to quantify the peptides. The lower m/z region of the HCD MS/MS 
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           Table 4.2. Experimental design and iTRAQ quantitation channel assignment. 
 
 
 
 
 
 
 
 
 
114 115 116 117
1 YSa YCb OSc OCd
2 YS YC OS OC
3 YS YC OS OC
4 YS YC OS OC
5 YC OS OC YS
6 YC OS OC YS
7 YC OS OC YS
8 OS OC YS YC
9 OS OC YS YC
10 OS OC YS YC
d Patients 70-85 years old who did not develop severe sepsis.
Experiment
Reporter ions
a Patients 50-65 years old who developed severe sepsis.
b Patients 50-65 years old who did not develop severe sepsis.
cPatients 70-85 years old who developed severe sepsis.
68 
 
  
spectra (inserts in Figure 4.1f and g) shows the intensity of the reporter ions which is used to 
quantify the peptides. As shown in Figures 4.1f and g, the ratios across the four groups are 1.0 : 
0.9 : 1.0 : 1.0 and 1.0 : 1.9 : 2.3 : 1.4 for reporter ions 114 : 115 : 116 : 117 from Complement C3 
and ApoCIII, respectively.   
Figure 4.2 shows a bar graph of the number of proteins and spectral counts (SCs) 
identified in each of ten biological replicate experiments. Also, the cumulative number of 
proteins identified is shown in Figure 4.2. An average of 283 ± 14 proteins and 59645 ± 4129 
SCs were identified and similar results were obtained across individual experiments. The total 
number of proteins identified increases with each pooled sample experiment such that a total of 
772 unique proteins were identified from all plasma samples. With more stringent criteria for 
protein filtering (i.e., at least two unique peptides), a total of 509 proteins were identified. A list 
of all identified proteins and peptides is provided in Supplemental Table S4.1 and S4.2. Based on 
SCs, the three most abundant proteins are Complement C3 (49,749 SCs), α-2-macroglobulin 
(47,273 SCs) and ApoAI (28,261 SCs).  
 
4.3.2 Western Analysis Verification  
Western blotting analysis was employed to generate a secondary measurement for several 
differentially-expressed proteins. Proteins involved in the acute phase response (i.e., CRP), 
coagulation pathway (i.e., FAC) pathway and lipid metabolism (i.e., ApoCIII) were selected. 
Figures 4.3a-c display Western blot data for CRP, FAC, ApoCIII, respectively. The histogram 
plots represent the normalized intensities corresponding to the density of the band spots for each 
group. The relative abundances (YS : YC : OS : OC) obtained from the Western blotting analysis 
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Figure 4.1. a) LC chromatogram for individual SCX fractions analyzed in triplicate. Example mass 
spectra of peptides eluted from b) SCX fraction 7 tr = 57.20 min with m/z 748.8046 and c) SCX fraction 6 
tr = 37.26 min with m/z 742.9010. CID MS/MS spectra are shown in d) and e), respectively. HCD 
MS/MS are shown in f) and g). The inserts are zoomed-in images of the f) and g) low m/z region. 
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Figure 4.2. Number of proteins (gray bars) and spectral counts (black bars) identified in each experiment. 
The cumulative number of proteins identified with each subsequent experiment (gray diamond) is also 
shown.   
 
 
 
 
 
 
72 
 
  
of CRP, FAC and ApoCIII were 1.0 : 0.4 : 0.4 : 1.8, 1.0 : 0.3 : 0.1 : 0.5, and 1.0 : 1.9 : 2.5 : 1.2, 
respectively. These observed Western data were similar to the measured iTRAQ results for these 
proteins (Table 4.3). However, suppression of iTRAQ protein ratios in MS/MS experiments is a 
noted limitation of this quantitative approach144. Proteomics workflows to handle suppression 
issues at the MS3 level have been recently reported168,172-174,197. 
 
4.3.3 Differentially-Expressed Proteins  
Protein ratios were obtained from both age groups: YS/YC in 50-65 years old group and 
OS/OC in 70-85 years old group using YC and OC as reference channels, respectively. Fifty-
eight differentially-expressed proteins (Table 4.3) were identified in comparisons from both age 
groups (i.e., YS/YC and OS/OC). Proteins differentially expressed between younger and older 
adults within each disease group (i.e., OC/YC and OS/YS) are provided in Supplemental Table 
S4.3 for interested readers. The measured fold-change values reported in the table include the 
mean and SD for each protein based on the ratios averaged across all biological replicates.  As 
shown in the Venn diagram (Figure 4.4), 28 proteins are differentially-expressed in 50-65 year 
olds adults (i.e., YS/YC) in which 14 have higher levels and 14 have lower levels in patients with 
severe sepsis compared to those with CAP. In the population of 70-85 year olds (i.e., OS/OC), 23 
proteins are differentially-expressed, in which 16 and seven have higher and lower levels in 
patients with severe sepsis, respectively. Of the 58 total differentially-expressed proteins, eight 
are in common amongst both age groups.  Interestingly, however the direction of the fold-change 
differs in younger and older adults. Specifically, α-1-anti-chymotrypsin (A1ACT), ApoE, FAC,  
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Figure 4.3. Western blotting images for a) C-reactive protein, b) fibrinogen α chain, and c) ApoCIII. The 
histogram under the images displays the normalized intensity ± standard deviation (N = 6) of the proteins 
across each group. The intensity for each individual band is normalized to the total intensity of the blot. 
 
 
 
 
 
 
a) b)
c)
)b)
74 
 
  
CRP, and LPS binding protein (LBP) levels were higher in younger adults with severe sepsis but 
lower in older adults with severe sepsis relative to age-matched controls, suggesting that lower 
levels of these proteins is associated with increased risk and incidence of severe sepsis in older 
adults. On the other hand, ApoAII, ApoCIII, and N-acetylmuranoyl-L-alanineamidase have 
lower and higher levels in younger and older with severe sepsis, respectively, suggesting that 
higher levels of these proteins may be factors for increased severe sepsis risk in older adults. 
 
4.3.4 Pathway Analysis  
Using IPA analysis, 19 biological pathways (Figure 4.5) are significantly over-
represented (p < 0.05) for the 58 differentially-expressed proteins. The most represented 
pathways include LXR/RXR activation and acute phase response signaling whereby 18 proteins 
are associated with each of these pathways. Many differentially-expressed proteins are involved 
in atherosclerosis signaling, interleukin (IL)-12 signaling and production of nitric oxide (NO) 
and reactive oxygen species (ROS) in macrophages, and endocytosis signaling. Fewer proteins 
are involved in the remaining biological pathways shown in Figure 4.5 such as actin cytoskeleton 
and IL-6 signaling. A list of the proteins associated with specific pathways is provided in 
Supplemental Table S4.4.  
 
4.4 DISCUSSION 
 This work investigates the effects of aging on the risk of severe sepsis in the acute plasma 
proteome of elderly CAP patients. While sepsis can occur as early as the neonatal stage198,199, 
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Figure 4.4. Venn diagram of differentially-expressed proteins for each age group (i.e., YS/YC 50-65 
years old and OS/OC 70-85 years old). The number of proteins that have higher (↑) or lower (↓) fold-
change values in each comparison are also shown. 
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Figure 4.5. Histogram plot of biological pathways associated with differentially-expressed proteins as a 
function of severity of sepsis (N = 58). The p value cutoff for the IPA pathways is p < 0.05.  
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incidence and morbidity increases with age and rises sharply after 65 years188,200,201 presumably 
due to immunosenescence50,189,201 and high levels of inflammatory proteins192-195,202. However, 
no significant differences with age have been reported for inflammatory and coagulation proteins 
and cell surface markers in patients with severe sepsis48. 
Our plasma proteomics study identified 58 differentially-expressed proteins in CAP 
patients that subsequently developed severe sepsis relative to those who did not in groups of 
elderly adults (Table 4.3). We note that some of the differences observed may be due to both a 
mixture of pre-existing conditions and differences in the initial acute phase response, as our 
study groups did not include a nonseptic subset. Below is a discussion of the proteins involved in 
the biological pathways such as acute phase signaling, coagulation pathway, and lipid 
metabolism. Other pathways are briefly discussed and the implications of these changes for 
understanding aging and severe sepsis in the elderly are presented. 
 
4.4.1 Acute Phase Response  
Sepsis is a pro-inflammatory state which is characterized by elevated levels of pro-
inflammatory cytokines, such as IL-6, IL-10 and tumor necrosis factor (TNF)-α23. These pro-
inflammatory cytokines regulate acute phase responses and the expression of acute phase 
proteins (APPs)203. Altered expression of APPs has been demonstrated in sepsis191,204-208. For 
example, increased levels of α-1-acid glycoprotein (A1AG), A1ACT, and LBP and decreased 
levels of transthyretin (TTR) are observed in 65 year old sepsis patients205,206 and cecal ligand 
and puncture (CLP) mouse207 and pig models208. It also appears that acute phase response  
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    Table 4.3. List of proteins that are differentially-expressed between groups. 
 
Acc. No.a Protein Name
YS/YC
(mean ± SDb)
OS/OC
(mean ± SD) n
c
O14791 Apolipoprotein L1 / 1.39 ± 0.70 10
O95445 Apolipoprotein M / 1.44 ± 0.48 8
P01008 Antithrombin-III 0.60 ± 0.06 / 10
P01011 Alpha-1-antichymotrypsin 1.58 ± 0.87 0.68 ± 0.18 10
P02649 Apolipoprotein E 2.11 ± 0.30 0.65 ± 0.17 10
P02652 Apolipoprotein A-II 0.50 ± 0.08 1.45 ± 0.46 10
P02654 Apolipoprotein C-I / 2.17 ± 1.02 10
P02656 Apolipoprotein C-III 0.69 ± 0.29 1.43 ± 0.77 10
P02671 Fibrinogen alpha chain 2.44 ± 0.72 0.60 ± 0.13 10
P02675 Fibrinogen beta chain 2.10 ± 0.58 / 10
P02679 Fibrinogen gamma chain 2.08 ± 0.72 / 10
P02735 Serum amyloid A protein 3.06 ± 1.09 / 10
P02741 C-reactive protein 3.27 ± 1.07 0.52 ± 0.22 10
P02749 Beta-2-glycoprotein 1 / 1.58 ± 0.61 10
P02750 Leucine-rich alpha-2-glycoprotein 2.14 ± 0.30 / 10
P02751 Fibronectin / 0.62 ± 0.31 10
P02753 Retinol-binding protein 4 0.53 ± 0.09 / 10
P02763 Alpha-1-acid glycoprotein 1 2.03 ± 0.43 / 10
P02766 Transthyretin 0.44 ± 0.09 / 10
P02774 Vitamin D-binding protein 0.57 ± 0.08 / 10
P02775 Platelet basic protein / 0.76 ± 0.21 9
P04114 Apolipoprotein B-100 1.52 ± 0.25 / 7
P04259 Keratin, type II cytoskeletal 6B 0.52 ± 0.06 / 7
P04275 von Willebrand factor 2.05 ± 0.34 / 10
P04278 Sex hormone-binding globulin 0.70 ± 0.26 / 7
P05090 Apolipoprotein D / 1.47 ± 0.32 10
P05154 Plasma serine protease inhibitor 0.73 ± 0.46 / 6
P05452 Tetranectin 0.64 ± 0.10 / 10
P05546 Heparin cofactor 2 0.71 ± 0.26 / 10
P06276 Cholinesterase / 1.45 ± 0.47 9
P06396 Gelsolin 0.55 ± 0.10 / 10
P07996 Thrombospondin-1 / 0.65 ± 0.34 6
P10909 Clusterin 0.73 ± 0.30 / 10
P13645 Keratin, type I cytoskeletal 10 0.58 ± 0.06 / 10
P15169 Carboxypeptidase N catalytic chain 1.31 ± 0.36 / 10
P16070 CD44 antigen 1.62 ± 0.55 / 7
P18428 Lipopolysaccharide-binding protein 2.20 ± 0.50 0.76 ± 0.32 10
P19652 Alpha-1-acid glycoprotein 2 2.17 ± 0.60 / 10
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Acc. No. Protein Name YS/YC(mean ± SD)
OS/OC
(mean ± SD) n
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 / 1.40 ± 0.53 10
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 / 1.58 ± 0.58 10
P20851 C4b-binding protein beta chain 1.39 ± 0.46 / 6
P29622 Kallistatin / 1.69 ± 0.57 10
P35542 Serum amyloid A-4 protein 0.48 ± 0.04 / 10
P35858 Insulin-like grow th factor-binding protein
 complex acid labile subunit
/ 1.39 ± 0.46 9
P61626 Lysozyme C 1.91 ± 0.96 / 8
P61769 Beta-2-microglobulin 1.89 ± 1.02 / 6
P80108 Phosphatidylinositol-glycan-specif ic 
phospholipase D
0.39 ± 0.06 / 9
Q03591 Complement factor H-related protein 1 1.31 ± 0.60 / 10
Q04756 Hepatocyte grow th factor activator / 1.81 ± 0.68 10
Q15431 Synaptonemal complex protein 1 / 1.37 ± 0.62 6
Q6UXB8 Peptidase inhibitor 16 / 2.03 ± 0.78 6
Q86UD1 Out at f irst protein homolog / 0.74 ± 0.19 6
Q86UV6 Tripartite motif-containing protein 74 / 1.85 ± 0.79 6
Q96KN2 Beta-Ala-His dipeptidase / 2.06 ± 0.93 6
Q96PD5 N-acetylmuramoyl-L-alanine amidase 0.58 ± 0.06 1.35 ± 0.39 10
Q9BXR6 Complement factor H-related protein 5 / 0.72 ± 0.18 10
Q9NXD2 Myotubularin-related protein 10 / 1.78 ± 0.69 7
Q9Y6R7 IgGFc-binding protein / 0.70 ± 0.26 9
c the number of experiments in which the corresponding proteins are quantified.
a accession number provided from the uniprot human database (04/25/2010, 20295 sequences).
b mean and SD values are calculated based on the reporter ion ratios for proteins quantified in at least 6 experiments.
Table 4.3. (continued) List of proteins that are differentially-expressed between groups. 
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increases with disease severity. For example, sepsis patients have higher levels of CRP and lower 
levels of serum amyloid A4 relative to patients with systemic inflammatory response syndrome 
(SIRS), another precursor to sepsis191,204.  
In our studies, 18 differentially-expressed proteins including CRP, LBP, A1ACT, and 
TTR are involved in acute phase response (Figure 4.5) and the levels in younger adults are 
consistent with other studies191,204-208. For example, CRP (fold-change YS/YC 3.27 ± 1.07), LBP 
(2.20 ± 0.50), A1ACT (1.58 ± 0.87), and A1AG (2.03 ± 0.43) have higher concentrations while 
TTR (0.44 ± 0.09) has lower concentrations in younger adults who developed severe sepsis 
compared to those did not. Acute phase response also varies depending on patient age. CRP 
(0.52 ± 0.22), LBP (0.76 ± 0.32), and A1ACT (0.68 ± 0.18) have lower concentrations in older 
adults who later developed severe sepsis suggesting that lower expression of these proteins at 
older age leads to severe sepsis. CRP and LBP have protective effects by neutralizing the toxicity 
of pathogens205,209-212, such that decreased expression of these proteins in older patients may help 
explain higher risk and mortality of severe sepsis.  Both aging and severe sepsis alter the immune 
system and response to infection213. Taken together, these results of acute phase response imply 
that a hypoinflammatory response in older adults may increase risk of severe sepsis, consistent 
with other literature reports23,214,215. 
 
4.4.2 Coagulation Pathway 
Pro-inflammatory cytokines can also activate the coagulation pathway. Briefly, the 
activation of a series of coagulation factors cleave prothrombin to thrombin, which in turn 
converts soluble fibrinogen into fibrin, upon which cross-linked fibrin forms blood clots23,216. In 
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sepsis patients, pro-coagulation overwhelms fibrinolysis (or anti-coagulation) leading to the 
presence of more blood clots23,216. This has been demonstrated by decreased levels of anti-
coagulant proteins [e.g., antithrombin III (ATIII), and heparin cofactor II] and increased levels of 
pro-coagulant proteins [e.g., fibrinogen, Von Willebrand factor (VWF)] in sepsis patients207,217-
219.  
In these studies, elevated levels of FAC (2.44 ± 0.58), fibrinogen beta chain (2.10 ± 
0.58), fibrinogen gamma chain (2.08 ± 0.72) and VWF (2.05 ± 0.34) were found in younger 
adults who developed severe sepsis. Fibrinogen has higher concentrations and ATIII has lower 
concentrations in sepsis207,217. Higher levels of VWF are associated with mortality in sepsis218. 
Higher levels of fibrinogen and VWF may indicate the presence of more blood clots in younger 
patients, consistent with literature reports219-221, whom developed severe sepsis. This notion is 
further supported by decreased concentrations of ATIII (0.60 ± 0.06) and heparin cofactor II 
(0.71 ± 0.26) in these studies. Interestingly, fibrinogen (0.60 ± 0.13) had lower levels in older 
adults who developed severe sepsis.  Our proteomics results support the notion that an acute 
response of reduced coagulation activity may be a contributing factor to higher incidence and 
mortality of severe sepsis found in older adults.  
 
4.4.3 Lipid Metabolism  
Apolipoproteins play important roles in liver X receptor/retinoid X receptor (LXR/RXR) 
activation and atherosclerosis signaling. For example, ApoB-100 can suppress the activation of 
LXR/RXR222. The activated LXR/RXR complex enhances the process of reverse cholesterol 
transport and cholesterol efflux, which transfers accumulated cholesterol from the blood vessel 
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walls to the liver for excretion223,224. Additionally, activated LXR/RXR can reduce the 
expression of pro-inflammatory cytokines (e.g., IL-6, IL-1β) by inhibition of the activity of 
transcription factor NF-κB225. The acute phase response which is activated during aging and 
severe sepsis can inhibit LXR/RXR activation226. Failed activation of the LXR/RXR complex 
may lead to atherosclerosis227,228, which is associated with severe sepsis229,230.  Apolipoproteins 
may have various biological functions by forming different lipoproteins [e.g., low density 
lipoproteins (LDL) and high density lipoproteins (HDL)]. For example, ApoB-100 is the protein 
component for LDL which is a cholesterol transporter231, whereas HDL formed by ApoA and 
ApoCIII can inhibit oxidation and inflammation35. 
Altered levels of apoliproteins have been reported in sepsis. For example, elevated levels 
of ApoB-100232 and lower concentrations of ApoCIII in response to inflammation233 have been 
reported. Consistent with this, we observed increased expression of ApoB-100 (1.52 ± 0.25) and 
decreased expression of ApoCIII (0.69 ± 0.29) in younger adults who developed severe sepsis. 
These changes may suggest suppressed activation of the LXR/RXR pathway and subsequent 
higher risk of atherosclerosis in younger adults (although we do not have data to support this 
notion). Additionally, ApoCIII has different isoforms based on the number (i.e., 0, 1, 2, and 3) of 
sialic acids per protein: ApoCIII-0, ApoCIII-1, ApoCIII-2, and ApoCIII-3234. The ApoCIII 
isoform ratios have been demonstrated to be correlated with mortality in younger severe sepsis 
patients (~ 49 years old)234. For example, the ratio of ApoCIII-2/ApoCIII-1 higher than may 
indicate increased risk of death in younger severe sepsis patients234. ApoE also has different 
isoforms: ApoE2, ApoE3, ApoE4. It has been shown that the levels of ApoE2 correlate 
positively with that of factor VIII, which is necessary for blood clotting235. Also, higher levels of 
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ApoE3 may reduce the risk of severe sepsis235. In this study, higher levels of ApoE (2.11 ± 0.30) 
were found in younger adults consistent with a rat model236, however lower levels (0.65 ± 0.17) 
were detected in older adults in our study. Also, higher levels of ApoCI (2.17 ± 1.02) and ApoM 
(1.44 ± 0.48) were detected in older adults who developed severe sepsis.  Although ApoCI levels 
correlate with the survivorship in ~ 25 year old severe sepsis patients237, higher concentration of 
ApoCI has been reported to promote atherosclerosis238,239. ApoM has also been reported to have 
lower concentrations in young adult severe sepsis patients 240,241 and contributes to the anti-
inflammatory response in sepsis241. Higher levels of ApoM in older adults who developed severe 
sepsis in our studies suggest that these patients have a reduced inflammatory state during acute 
response. That lipid metabolism is altered in these studies points to atherosclerosis as a 
contributing factor of severe sepsis incidence; however further analyses are necessary to support 
this hypothesis. 
 
4.4.4 Other Pathways  
Other key pathways identified in these studies such as IL-12 and IL-6 signaling support a 
hypoinflammatory response in older adults (Table 4.3)242. Enhanced production of NO and ROS 
in macrophages has been previously reported in aging and sepsis243,244. We detect differentially-
expressed proteins involved in the production of NO and ROS (i.e., retinol binding protein 1, 
lysozyme C and clusterin) which support elevated oxidative stress in the elderly244,245 and severe 
sepsis patients243,246. 
The nested-case control study design employed herein has identified many potential 
factors that may contribute to higher incidence of severe sepsis in adults older than 65. There is a 
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substantial role of inflammation and coagulation processes in acute host response and our 
proteomics results suggest that older individuals have hypoinflammatory and reduced 
coagulation responses. While other factors such as lipid metabolism and production of ROS are 
implicated, additional experiments are necessary in order to determine better the effects of age 
on these processes. For example, it would be worthwhile in future studies to measure oxidative 
stress markers in this CAP cohort and to examine the correlation between incidence of severe 
sepsis and age with atherosclerosis. A limitation to these studies is the small sample populations 
(N = 10) used to measure a wide range of proteins that are known to vary substantially in plasma 
tissue117. Future studies include selecting key proteins to follow their expression levels in a larger 
cohort using an independent method, such as ELISA. 
 
4.5 CONCLUSIONS  
 The incidence and mortality of severe sepsis increases with aging, especially after 65 
years. This study investigated the effects of aging on initial host response to sepsis in CAP 
patients who eventually develop severe sepsis after hospitalization. Using a proteomics 
approach, several altered biological pathways were identified. Acute phase response and 
coagulation were highly represented in these studies, and novel pathways such as lipid 
metabolism, atherosclerosis, and production of NO and ROS were observed. Interestingly, 
differentially-expressed proteins involved in these pathways show opposite expression levels of 
change dependent on patient age (i.e., 50-65 and 70-85 years old). These findings provide more 
insight to factors that may explain higher risk, increased incidence, and mortality in older adults 
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with severe sepsis. Such insight will be helpful for the development of age-specific and 
personalized severe sepsis treatments.  
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5.0 PROTEOME CHARACTERIZATION OF SPLENOCYTES FROM AN APP/PS-1 
ALZHEIMER’S DISEASE MODEL247* 
(*note that information in the chapter is written based on a published paper, Cao, Z.; Robinson, R. A. S. 
Proteomics 2014, 14, 291) 
5.1 INTRODUCTION 
Currently, there are ~ 27 million Alzheimer’s disease (AD) patients worldwide and it is 
predicted that one in 85 people globally will be diagnosed with AD by 2050248. AD is a 
neurodegenerative disorder with symptoms that include progressive memory deficits, cognitive 
impairment and changes in behavior and personality248. Pathological hallmarks of the disease in 
the brains of AD patients include senile plaques (SP) and neurofibrillary tangles as well as 
mitochondrial dysfunction, oxidative stress, and neuronal loss248. SP are composed of amyloid β 
(Aβ) peptides which are generated from the cleavage of amyloid precursor protein (APP) by β- 
and γ-secretases248,249. Mutations in the genes coding APP and presenilin-1 (PS-1), which is a 
sub-component of γ-secretase, are present in familial AD and are associated with increased 
incidence of AD249.  
Recently, studies focused on the alteration of the immune system in the AD brain and 
periphery have attracted considerable attention. An increased number of activated microglia has 
been reported in AD brain250. Elevated levels of interleukin (IL)-1β, IL-6, and tumor necrosis 
factor (TNF)-α may contribute to AD pathology250. The number of macrophages is reduced in 
AD251 and spleen tissues from a triple transgenic (APP×PS-1×tau) AD mouse model have 
decreased dendritic cells252. The activation of natural killer (NK) cells is suppressed in AD70. 
Subpopulations of T-cells (e.g., CD4+ and CD8+) in the AD peripheral immune system also 
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change, although there are conflicting reports252,253. Furthermore, since the blood-brain barrier 
(BBB) is compromised in AD250,251, changes in the peripheral immune system may also affect 
the function of brain250,251.  
APP/PS-1 mice have increased Aβ production and accelerated Aβ deposits254. By 12 
months of age, numerous SPs are present in the hippocampus and caudal cortex254 and animals 
exhibit decreased speed of relearning than controls254. Increased protein oxidation and lipid 
peroxidation and proteome alterations have been observed in brain and neurons from APP/PS-1 
mice79,80,255-257. CD90+ cells and a heterogenerous mixture of CD90- cells in APP/PS-1mice 
have increased oxidative stress (Chapter 6)255. Additionally, the immune system in the brain and 
periphery is altered as evidenced by increased activation of microglia81,258, alterations in the 
distribution of monocytes259 and the cell cycle of lymphocytes84.  
Recently, it has been reported that peripheral immune cells behave differently in AD260. 
For example, the number of B-cells is lower in AD while no changes are observed in the number 
of T-cells. To-date there are no proteomics reports however, which focus on the analysis of the 
various immune cell populations in the context of AD.  This work represents one of the first 
studies to characterize protein expression in different peripheral immune cell types in an AD 
mouse model. Herein, we provide the first proteome map of splenocyte populations in a human 
double transgenic knock-in APP/PS-1 mouse model to serve as a reference for proteome studies 
aimed at elucidating the role of peripheral immunity in AD.  
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5.2 EXPERIMENTAL AND MATERIALS 
5.2.1 Animals  
APP/PS-1 male mice [B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, stock number 
005864, genetic background C57BL/6J]254 were purchased from Jackson Laboratory and housed 
in the Division of Laboratory Animal Resources at the University of Pittsburgh. Mice were fed 
standard Purina rodent laboratory chow ad libitum on a 12 h light/dark cycle. All animal 
protocols were approved by the Institutional Animal Care and Use Committee at the University 
of Pittsburgh.  
 
5.2.2 Splenocyte Isolation  
Spleen tissue was mashed to obtain a single cell suspension. CD90.2 magnetic 
microbeads (MiltenyiBiotec, Auburn, CA, USA) were employed to separate splenocytes into two 
subsets: CD90+ and CD90-. CD90.2 recognizes the Thy1.2 antigen in peripheral T-cells from 
lymphoid organs and blood in inbred mouse strains (e.g., C57BL/6J). The CD90- subset contains 
a heterogenerous mixture of B-cells, macrophages, and NK cells.  
 
5.2.3 Protein Extraction and Digestion  
Proteins were extracted from CD90+ or CD90- subsets with RIPA buffer255. Rapid 
freezing and thawing was repeated three times to lyse cells. The solution was centrifuged at 
14,000g at 4ºC for 20 min to remove cellular debris. Supernatant was collected and protein 
concentration determined by a BCA assay (Thermo Scientific; Waltham, MA, USA). Sample 
pooling was employed in this study due to the limited amount of proteins extracted from CD90+ 
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and CD90- cells from each individual mouse 261,262. Additionally, it has been demonstrated that 
sample pooling is useful for characterization of the population rather than each individual261,262 
which was adopted for this global study. Proteins from CD90+ and CD90- subsets isolated from 
six AD male mice (14 months of age) were pooled and acetone precipitated. Protein pellets were 
suspended in 0.1% w/v RapiGest SF (Waters, Milford, MA, USA) solution in 50 mM NH4HCO3, 
reduced with dithiothreitol, alkylated with iodoacetamide, and digested with TPCK-treated 
trypsin (Sigma-Aldrich, St. Louis, MO, USA). Trifluoroacetic acid was added and incubated for 
45 min at 37 ºC to quench digestion. Samples were centrifuged at 13,000 rpm for 10 min, the 
supernatant cleaned with an Oasis HLB cartridge (Waters; Milford, MA, USA), and dried with a 
SpeedVac.  
 
5.2.4 Offline SCX-LC-MS/MS Analysis  
Digests were fractionated into strong cation exchange (SCX) fractions and subject to 
triplicate LC-MS/MS analyses on a LTQ Orbitrap Velos MS instrument. Procedures are similar 
to those used in Chapter 2 and 497,130 whereby mobile phase A and B for these analyses were 
3% (v/v) acetonitrile with 0.1% formic acid and 100% (v/v) acetonitrile with 0.1% formic acid, 
respectively. However, the LC gradient was modified as follows: 0-15 min, 10% mobile phase 
B; 15-315 min, 10-40% B; 315-410 min, 40-60% B; 410-425 min, 60-90% B; 425-439 min, 90% 
B; 439-440 min, 10% B; 440-480 min, 10% B. The reversed-phase analytical column was 75 µm 
i.d. × 26 cm. MS survey scans were performed in the Orbitrap (R = 60,000) over 300-1800 m/z 
and top 10 CID data dependent acquisition was performed in the LTQ.  
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5.2.5 Data Analysis  
.RAW files were analyzed with Proteome Discoverer 1.3 software. MS/MS spectra were 
searched against the IPI mouse database (08/16/2012, 59534 sequences). SEQUEST search 
parameters were as follows: two maximum trypsin miscleavages; precursor and fragment mass 
tolerances of 10 ppm and 0.8 Da, respectively; carbamidomethyl modification on cysteine was a 
static modification; oxidation of methionine was a dynamic modification. Decoy database 
searching was employed to control the false discovery rate (FDR) and generate lists of peptides 
with high (FDR < 0.01) and medium (FDR < 0.05) confidence. 
 
5.3 RESULTS AND DISCUSSION 
Splenocytes were separated into CD90+ and CD90- subset, and the purity of each subset is 
~ 95% as shown in the flow cytometry results (Figure 5.1). Splenocyte counts were 2.96 ± 0.33 × 
107 cells and 6.46 ± 0.70 × 107 (mean ± standard deviation, N = 6) cells in the CD90+ and 
CD90- subsets, respectively. Few studies report the absolute number of T-cells isolated from 
mouse spleen tissues, however, the percentage of T-cells (31%) is similar to that observed in 
other AD mouse models252. Offline SCX-LC MS/MS analysis led to identification of 1092 and 
1223 unique peptides in the CD90+ and CD90- subsets, respectively. Overall, 906 proteins were 
identified in both subsets (Figure 5.2) and with more stringent criteria [(e.g., at least two spectral 
counts (SCs) for each protein) this number reduces to 711 proteins. Additionally, 275 and 334 
proteins are unique to CD90+ and CD90- subsets, respectively (Figure 5.2), implying no SCs 
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were detected for these proteins in the other subset. A list of proteins and peptides identified in 
this study is provided in Supplemental Table S5.1 and S5.2, respectively.  
ProteinCenter software (Thermo Scientific; Waltham, MA, USA) was employed to 
characterize proteins identified in CD90+ and CD90- subsets, and they show similar distributions 
with regards to cellular components, biological processes, and molecular functions (Figure 5.2b-
d). Identified proteins were distributed into 17 cellular locations (Figure 5.2b) with cytoplasmic 
proteins (24.9% and 23.8% for CD90+ and CD90- subset, respectively) representing a large 
portion of each dataset. Cytoskeletal proteins including actin-related proteins (e.g., moesin, 
cofilin-1, talin-1, and Roh family proteins) were also identified in both of the cell subsets (Figure 
5.2b). Altered levels of cytoskeletal proteins have been reported to cause neuronal death in AD 
263, however, no proteomics studies show how these proteins affect peripheral immune cell 
function. Within the context of the immune system, cytoskeletal proteins play vital roles in cell 
migration. Recently, increased recruitment of immune cells (e.g., T-cells, dendritic cells and 
monocytes) to the brain during neuroinflammation in AD has been reported264-266.  Additionally, 
alterations in the levels of cytoskeletal proteins may affect the division, proliferation, and 
activation of immune cells.  Individual cytoskeletal proteins, such as annexin A5 and profilin-1, 
have higher SCs in CD90+ cells whereas myosin and ezrin have higher SCs in CD90- cells.  
Identified proteins were also characterized by biological processes (Figure 5.2c). The top 
three processes were metabolic, regulation of biological process, and response to stimulus. 
Increased stimulation of T-cells has been reported in AD, which may be caused by toxic 
molecules (e.g., Aβ) crossing the BBB74,251. Cytokines produced by activated T-cells promote the 
stimulation of other immune cells (e.g., macrophages and monocytes)74. Thus, proteins involved  
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Figure 5.1. a) Proteomics workflow which includes harvesting of splenocytes, sample preparation, and 
LC-MS/MS analysis.  An anti-CD90.2 antibody conjugated with phycoerythrin (PE) was employed to 
label CD90+ T-cells in the flow cytometry experiment. Plots of isolated cell populations of b) all cells 
before magnetic bead separation, c) CD90- subsets, and d) CD90+ T-cells. 
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in response to stimulus for example, should be detected in both subsets.  As an example, we 
observe Thy-1 membrane glycoprotein (or CD90) and lysozyme C-2 in CD90+ and CD90- 
subset, respectively. Proteins involved in cell differentiation (3.5%), proliferation (2.4%), 
division (0.8%), and growth (0.3%) were also identified. Characterizing the proteins identified in 
these processes may help shed light on the behavior in AD immune cells.  For example, 
conflicting results have been reported about the proliferative response of T-cells in AD267,268. Our 
studies have identified calponin-2 and calreticulin, for example, which are involved in 
proliferation, and are identified in CD90+ and CD90- subset, respectively. 
The most abundant molecular functions were protein binding, catalytic activity, and 
nucleotide binding (Figure 5.2d). Notably, ten and 14 antioxidant proteins which are involved in 
oxidative stress [e.g., glutathione peroxidase-1 (GPx-1) and thioredoxin reductase 1] were 
identified in CD90+ and CD90-, respectively. For example, GPx-1 protects tissues and cells 
from oxidative damage by reduction of reactive oxygen species. Increased activity of GPx-1 may 
indicate elevated oxidative stress269. Increased oxidative stress in the brain has been implicated in 
the pathogenesis and progression of AD270. Recently, our laboratory measured that oxidative 
stress, as evidenced by elevated levels of 3-nitro-tyrosine and protein carbonylation, increased in 
CD90+ and CD90- subsets during AD progression (Chapter 6)255. GPx-1 has a higher rank in 
CD90- as compared to CD90+ cells. These results correlate with the higher levels of oxidative 
stress observed in CD90- cells255. Identification of these antioxidant proteins and how they are 
distributed in the CD90+ and CD90- subsets sheds light on the pathways that may lead to global 
oxidative stress in this model 255,257.  
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Figure 5.2. a) Venn diagram of the number of proteins identified in CD90+ and CD90- subsets with 
associated biological processes listed. Histogram plots of the percentage of proteins identified in CD90+ 
(black rectanguler) and CD90- (gray rectanguler) involved in a specific b) cellular component, c) 
biological function, and d) molecular function based on ProteinCenter analyses. 
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To better study the proteome of CD90+ and CD90- cells, the biological functions of 
proteins unique to each subset were compared. Proteins associated with transcription and protein 
translation were significantly overrepresented in CD90+ cells whereas DNA replication, free 
radical scavenging, and antigen processing were significantly overrepresented in CD90- cells 
(Figure 5.2a). Rank of protein abundance 271,272-a robust measurement based on SCs 271,272-for 
proteins identified in both CD90+ and CD90- subsets was also compared (Figure 5.3). One 
hundred and eighty-nine proteins have similar rank (data not shown) between CD90+ and CD90- 
subsets and are significantly involved in RNA post-transcriptional modification, post-
translational modification, protein folding, cell death and survival, and DNA replication. The 
most abundant protein in CD90+ and CD90- cells are histone H2AZ and heat shock cognate 71 
kDa proteins, respectively. Of the 297 proteins that overlap between cells, 47 proteins have a 
higher rank in CD90+ cells (Figure 5.3a) and are involved in protein translation, cellular function 
and maintenance, energy production, and lipid metabolism. Annexin A5, a cytoskeletal protein 
which maintains cellular function, was selected for Western blotting analysis. Similar to the 
proteomics data, annexin A5 has higher abundance in CD90+ cells (Figure 5.3a inserts). Fifty-
nine proteins have higher rank in CD90- cells (Figure 5.3b) and are involved in free radical 
scavenging, cell signaling, and post-translational modification. Assessing the relative abundances 
of proteins in each subset as well as identifying proteins unique to a specific subset may help 
with understanding the role of each protein in AD. 
Finally, proteins from CD90+ and CD90- subset were further compared by biological 
pathways. Eighteen and 19 pathways were identified for CD90+ and CD90- subset, respectively 
(Supplemental Table S5.3). Pathways related to energy metabolism are identified in both of 
96 
 
  
CD90+ and CD90- subset, such as citrate cycle, glycolysis/gluconegenesis, and oxidative 
phosphorylation. Notably, CD90+ proteins are involved in the pathways associated with 
dementia including AD. As shown in Figure 5.4a, six proteins in AD are detected in this study, 
which have higher rank in CD90+ cells. Out of the six proteins, four mitochondrial proteins were 
identified (Figure 5.4a): complex I (NADH Dehydrogenase, C-I), complex IV (or cytochrome c 
oxidase, C-IV), complex V (or ATP synthase, C-V), and cytochrome c (CytC), which regulate 
energy metabolism, oxidative stress, and apoptosis250,273.  Deficiencies of C-I and C-IV may 
induce higher concentration of reactive oxygen species and inhibit production of ATP in 
AD250,274 whereas C-V is related to T-cell proliferation and activation275. Increased oxidative 
stress leads to the release of CytC to the cytoplasm resulting in apoptosis276. The roles of 
peripheral mitochondrial proteins in AD has been reviewed recently277. 
However, phagosome and antigen processing and presentation are uniquely identified for 
CD90- proteins, which are consistent with the function of CD90- cells (e.g., macrophages, 
dendritic cells, and neutrophils). In this study, eight proteins detected in the CD90- cells are 
involved in antigen processing and presentation (Figure 5.4b). For example, calnexin (CANX), 
which is essential for the assembly of major histocompatibility complex278, was observed in this 
study. Alterations in the levels of CANX have been reported in AD274.    
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Figure 5.3. Heatmap display of protein abundance rank for proteins which have higher abundance in a) 
CD90+ (N = 47) and b) CD90- (N = 59) subsets, respectively. Insert in a) shows the Western blotting 
data for annexin A5. 
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Figure 5.4. KEGG pathway analysis of the a) Alzheimer’s disease and b) Antigen processing and 
presentation pathways for CD90+ and CD90- proteins identified in this study, respectively (denoted by 
red label and box). 
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5.4 CONCLUSIONS 
This work has provided a comprehensive map of CD90+ and CD90- splenocytes in 
double transgenic APP/PS-1 mice. Nine hundred and six proteins were identified and are 
involved in various biological pathways, such as dementia, antigen processing and presentation, 
and energy metabolism. Proteome comparison of specific subsets of splenocytes may help 
provide better insight into AD pathology.  
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6.0 OXIDATIVE STRESS IN CD90+ T-CELLS OF APP/PS-1 TRANSGENIC 
MICE255* 
(*note that information in this chapter is written based on a published paper, Robinson, R. A. S.; Cao, Z.; 
Williams, C. Journal of Alzheimer's Disease 2013, 37, 661) 
6.1 INTRODUCTION 
The immune system has been linked to the etiology of AD and may serve as an early 
marker of disease74,279-284.  In AD patients, suppressor cells and helper T-cells have abnormal 
function285,286, decreased proliferative activity268,287, activation responses288, and functionality of 
natural killer (NK) cells289.  Conflicting reports exist however, with regards to the changes of 
specific cell types.  For example, the number of T- and NK cells are reported as unchanged in 
AD patients70,290, while in other studies, the levels of CD8+ and CD3+ T-cells, CD19+ B-cells, 
and NK cells are decreased in AD patients compared to age-matched controls70,252,266,286,291,292. 
Cytokine levels in the periphery vary287,293-296 and AD patients have a lessened T-cell 
proliferative response to amyloid beta precursor protein (APP) peptides268 and other antigenic 
factors297,298. Additional factors that may contribute to altered immunity in AD patients are 
telomere shortening299, intracellular calcium response300, and oxidative stress301.     
Consistent with findings in human patients, altered immunity has recently been reported 
in a triple transgenic (3xTg) AD mouse model74. Based on lower thymus weights, chemotaxis 
function, proliferation, anti-tumoral NK activity, and interleukin (IL)-2 levels in younger 3xTg-
AD mice, it is apparent that the immune system can be used as an early marker of disease74.  
Older 3xTg-AD mice have higher chemotaxis function and IL-2 secretion in comparison to 
controls74.  Predisposition to systemic immune challenges during late neonatal stages of 
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development, leads to AD-like pathology in wild-type (WT) mice that becomes more 
pronounced if there is additional exposure to immune challenge during adulthood280. Such 
findings imply that systemic immune challenges or peripheral dysfunction can be risk factors for 
developing AD.   
Interestingly, oxidative stress is also implicated in the immune system of 3xTg AD mice; 
lower activity of antioxidants glutathione peroxidase, glutathione reductase, and total glutathione 
and increased xanthine oxidative activity is observed in spleen of 3xTg AD mice74.  Because of 
the correlation of these changes with premature immunosenescence, oxidative stress appears to 
be a precursor of altered immune function and/or disease pathogenesis in AD. We sought to 
determine if oxidative stress is present in the peripheral immune system of a double transgenic 
AD mouse model that has mutations in the genes coding APP and presenilin-1 (PS-1), a sub-
component of γ-secretase.  Mutations in APP and PS-1 are present in familial AD and are 
associated with increased incidence of AD249.   
 
6.2 EXPERIMENTAL AND MATERIALS 
6.2.1  Animals 
APP/PS-1 male mice [B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, stock number 
005864, genetic background C57BL/6J express the chimeric mouse/human (Mo/Hu) APP695swe 
(i.e., K595N and M596L) and a mutant human PS1-dE9254,302 were purchased from Jackson 
Laboratory and housed in the Division of Laboratory Animal Resources at the University of 
Pittsburgh. Mice were fed standard Purina rodent laboratory chow ad libitum on a 12 h light/dark 
cycle. All animal protocols were approved by the Institutional Animal Care and Use Committee 
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at the University of Pittsburgh. Spleen tissues were harvested from control and AD mice at three, 
seven, and 12 months which correspond to time points before, during, and after the pathological 
and physical symptoms of AD254,302. 
 
6.2.2 Splenocytes Isolation 
Spleen tissue was mashed to obtain single cell suspensions and CD90.2 magnetic 
microbeads (MiltenyiBiotec Inc. Auburn, CA, USA) were used to separate T-cells (hereafter 
referred to as CD90+ T-cells) from other non T-cell populations (e.g., B-cells, NK cells, 
macrophages; hereafter referred to as CD90- cells) according to manufacturer’s instruction. 
Proteins were extracted with RIPA buffer and three cycles of rapid freezing and thawing was 
performed to lyse cells. Samples were centrifuged at 14,000 g at 4 ºC for 20 min to remove 
cellular debris. Supernatant was collected and protein concentration was determined by BCA 
assay.  An aliquot of the sample was acetone precipitated and reconstituted in PBS buffer for 
further analyses.  
 
6.2.3 Oxidative Stress Measurements 
For PCO measurements, five µL of each sample was incubated with 12% SDS and 20 
mM 2,4-Dinitrophenylhydrazine (DNPH) solution for 20 min at room temperature. For 3NT 
measurements, five µL of each sample was incubated with 12% SDS and Laemmli buffer for 20 
min at room temperature. A neutralization solution was added to stop the reaction. Derivatized 
proteins (250 ng) were loaded onto a nitrocellulose membrane with a slot blot apparatus. The 
membranes were blocked with 3% (w/v) BSA solution overnight at 4 ºC and incubated with a 1 : 
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2000 dilution of anti-DNP antibody (Millipore, Billerica, MA, USA) or a 1 : 2500 dilution of 
anti-3-nitrotyrosine antibody produced in mouse (Sigma-Aldrich, St Louis, MO, USA) for 2 
hours. After four cycles of rinsing, anti-rabbit IgG alkaline phosphatase secondary antibody 
(Sigma) or anti-mouse IgG alkaline phosphatase (Sigma-Aldrich, St Louis, MO, USA) was 
added with the dilution factor 1 : 5000 and incubated with membranes for 1 h. The membranes 
were washed in wash blot and developed using 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP)/nitro blue terazolium chloride (NBT) color-imetric development. Blots were dried, 
scanned and quantitated with Scion Image. The data was analyzed using two-way ANOVA (p < 
0.05) testing with Origin 8.0.  
 
6.3 RESULTS AND DISCUSSION 
Proteins extracted from CD90+ T-cells and CD90- cells were used to measure global 
levels of common oxidative stress parameters-PCO and 3NT (Figure 6.1). Samples from three-
month old WT were set as the controls and different age groups and genotype (i.e., AD) were 
compared to the control levels. WT mice exhibit increased levels of PCO and 3NT in both 
CD90+ T-cells and CD90- cells with increasing age.  The effects are more pronounced between 
each age group for PCO and 3NT levels measured in CD90- cells and 3NT levels measured in 
CD90+ T-cells.  For example, in CD90+ T-cells, there is an ~ 80% increase in 3NT levels from 
seven to 12 months (Figure 6.1c).  APP/PS-1 mice also exhibit age-dependent increases in PCO 
and 3NT levels in CD90+ T-cells and CD90- cells.  Larger differences in oxidative levels exist 
between seven and 12 months, which correlates with increased Aβ deposition in the brain254,302.  
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For example, in CD90+ T-cells there are  ~ 80% and ~ 100% increases in PCO (Figure 6.1a) and 
3NT (Figure 6.1c) levels, respectively, from seven to 12 months in APP/PS-1 mice. Finally, from 
the ANOVA analysis there is also a significant difference in oxidative PCO levels between WT 
and APP/PS-1 mice at seven and 12 months (Figure 6.1a, p < 0.01 and p < 0.05).  
Oxidative stress plays a significant role in the pathogenesis of AD as has been evidenced 
by measurements in brain79,303, plasma 304-306, cerebrospinal fluid270,307, and other tissues such as 
heart307-309. Recently, there has been evidence to suggest that oxidative stress levels are elevated 
in the peripheral immune system of AD patients or mouse models74,310 leading to new insight to 
this disorder.  Our results are consistent with these findings and suggest that oxidative stress is 
present in the peripheral immune system of an AD mouse model and that these levels increase in 
an age-dependent manner that tracks disease progression.  These findings are based on measures 
of global protein oxidation which are commonly used to assess oxidative stress in many 
disorders including AD311-313.   
The APP/PS-1 model used in these studies has been used extensively to study aspects of 
familial AD79,254,302.  While APP/PS-1 do not have neurofibrillary tangles, they do repeatedly 
display symptoms such as memory loss, impairment in learning ability, and decreased cognition 
as a function of age254,302. By nine months of age, Aβ deposition occurs in the brains of these 
mice, resulting in SP formation by 12 months254,302  and increases in plaque formation can be 
correlated with augmented levels of Aβ(1-42)254,302and oxidative stress79,303,312. Most relevant to 
this work is the evidence which links altered immunity to neurodegeneration in this model. It has 
been reported that immunization with glatiramer acetate and myelin oligodendrocyte 
glycoprotein-derived peptide (targets of immune cells) improve Aβ clearance, memory and  
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Figure 6.1. Histogram plots for levels of protein carbonylation (PCO) and 3-nitrotyrosine (3NT) in 
CD90+ T-cells and CD90- cells isolated from control (gray rectangular) and AD (black rectangular) mice 
at three, seven, and 12 months. Intensities are normalized to three-month old WT controls (N = 6). Error 
bar: ± SEM. * p < 0.01, ** p < 0.05.  
 
a) b)
c) d)
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learning, and increase anti-inflammatory cytokines and reduce pro-inflammatory cytokines in 
macrophages314-316. Additionally, the CD90+ T-cell proteome of this AD mouse model has 
recently been characterized by our laboratory and includes the identification of many proteins 
involved in free radical scavenging and transcription and translational processes (Chapter 5)247. 
To-date there are no reports of oxidative stress in the peripheral immune system of 
APP/PS-1 mice.  Based on studies in the 3xTgAD model which point to oxidative stress as an 
early indicator of disease pathogenesis, our results reported herein are consistent with this notion.  
As the levels of PCO and 3NT increase with disease progression in this model, oxidative stress 
measurements in CD90+ T-cells could be used as an early sign of AD.  It is clear that elevated 
oxidative stress in CD90+ T-cells and CD90- cells is also partially related to immunosenescence 
as both WT and APP/PS-1 mice exhibit age-dependent changes in levels. In order to better 
understand the relationship between oxidative stress and its effects on immune function and 
inflammation pathways, we have initiated a large-scale proteomics study of CD90+ T-cells with 
disease progression in APP/PS-1 mice (Chapter 7). Those studies report on many proteins 
involved in oxidative stress and immune pathways such as aldose reductase, granzymes A and B, 
and lamin1. Due to low concentrations and the necessity for enrichment, no cytokines were 
observed in CD90+ T-cells.  
 
6.4 CONCLUSIONS 
In conclusion, this work presents the first report of oxidative stress measurements in 
CD90+ T-cells and CD90- cells in APP/PS-1 mice and shows that PCO and 3NT levels may be 
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useful for measuring early signs of AD and tracking disease progression in peripheral immune 
tissue. Future studies may include understanding the effects of oxidative stress on immune 
function in APP/PS-1 and/or human subjects.   
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7.0 TRACKING THE T-CELL PROTEOME DURING THE PROGRESSION OF 
ALZHEIMER’S DISEASE 
7.1 INTRODUCTION 
Alzheimer’s disease (AD) currently affects ~ 27 million people worldwide and it is 
predicted that this number will double every 20 years until at least 2040248,317. Clinically, AD 
patients are characterized by progressive memory deficits, cognitive impairment, and changes in 
behavior and personality248,317. It is clear that alterations in the central nervous system (CNS) 
play important roles in the pathology of AD. Such alterations include the accumulation of senile 
plaques (SP) and neurofibrillary tangles (NFTs), regionalized neuronal death, loss of synaptic 
connections, increased oxidative stress, mitochondrial dysfunction, and reduced energy 
metabolism303,318,319. Neuroinflammation, which is manifested by activated microglia and 
astrocytes and increased levels of cytokines and chemokines, is observed in AD CNS64,320.  
While AD is primarily characterized by changes in the CNS alterations in peripheral 
immunity may also contribute to disease etiology. Impaired peripheral immunity is associated 
with AD and other neurodegenerative disorders including Parkinson’s disease (PD), 
Huntington’s disease (HD), Down syndrome (DS), amyotrophic lateral sclerosis (ALS), and 
multiple sclerosis321-324. Low-grade chronic inflammation associated with aging increases the 
risk of AD in the elderly321. Inflammation caused by infectious agents may also contribute to the 
pathogenesis of AD325. Herpes simplex virus type 1 (HSV-1), a neurotropic virus, has been 
found in AD brain325 and is observed in the elderly326. Cytomegalovirus also increases the risk of 
AD which is related to compromised immunity caused by infection326.  
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Dysfunctional immune cells are present in AD. Macrophages and monocytes have 
lessened phagocytic ability 68,69. The cytotoxic function of natural killer (NK) cells is impaired 
although no changes are observed in the number of NK cells70. The number and anti-amyloid β 
(Aβ) response of B-cells is lower in AD321,327. Conflicting reports exist regarding T-cells69. For 
example, some studies report decreased numbers of T-cells in AD patients292,328  whereas others 
found no changes321,329. AD patients have decreased numbers of naïve T-cells but increased 
numbers of memory cells 321, consistent with the elderly330. Shortened telomeres in T-cells331 
result in increased production of pro-inflammatory cytokines [e.g., interleukin (IL)-6 and tumor 
necrosis factor (TNF)-α] and natural killer-like activities331. T-cells also have elevated calcium 
response300, increased apoptosis332, and hyper-activity73. 
Communication between the peripheral immune system and CNS affects AD brain 
function. Monocytes and T-cells infiltrate the AD brain67.  Once in the brain, these cells can 
activate microglia and exacerbate neuroinflammation and Aβ precipitation321. For example, IL-2 
in the brain damages neuronal integrity333. Interferon-γ produced by T-helper 1 cells promotes 
SP formation334. Peripheral immune cells can exert damaging effects on the brain without 
directly entering the CNS. For example, cytokines secreted by peripheral T-cells, monocytes and 
macrophages can cross the blood-brain barrier (BBB) and enhance neuroinflammation, while the 
cells themselves do not cross the BBB321,335.  
Mouse models represent an important means to investigate the immunopathology of AD 
and in fact dysfunction of the immune system in various mouse models has been reported. In 
triple transgenic (3xTg) AD mice, reduced weight of immune organs (e.g., thymus, spleen, and 
adrenal glands) indicates premature immunosenescence74. 3xTg mice have decreased 
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chemotaxis, antitumoral natural killer activity, and IL-2 secretion74 and show signs of systemic 
autoimmunity75. Regulation of the inflammatory response by blocking IL-1 signaling attenuates 
cognitive defects in 3xTg mice76. Human double transgenic knock-in amyloid precursor 
protein/presenilin-1 mouse (APP/PS-1) is another important AD model78,254. APP/PS-1 mice 
have increased oxidative stress in T-cells that is exacerbated with later stages of disease 
(Chapter 6)336. Additionally, they have increased activation of microglia81,82, altered monocyte 
subpopulations337, and enhanced lymphocytes proliferation84. Aβ deposition in APP/PS-1 mouse 
brain is accompanied by T-cell infiltration caused by respiratory infection338. Such findings from 
AD mouse models help to better elucidate the role of immunity in AD pathogenesis. 
Furthermore, changes in immune cells may provide novel biomarkers for diagnosis and 
treatment of AD. 
Recently, our laboratory compared the proteome of CD90+ T-cells and CD90- cells from 
APP/PS-1 mice and identified that CD90+ proteins are more involved in transcription and 
translation, whereas CD90- proteins are more involved in DNA replication, free radical 
scavenging, and antigen processing (Chapter 5)247. Based on this APP/PS-1 splenocyte 
reference map, we extend our proteomics investigation of immune cells in APP/PS-1 mice in this 
work. Specifically, the CD90+ T-cell proteome of APP/PS-1 mice is  compared to age-matched 
wild-type (WT) controls at three, seven, and 12 months of age. At three months, APP/PS-1 mice 
behave similarly to WT. At seven months, Aβ plaques start to deposit in the brain and mice 
mimic the cognitive deficits associated with early stages of AD78,254. By 12 months of age, 
numerous SP are present in the hippocampus and caudal cortex78,254. Here, CD90+ T-cell 
proteins are digested, and tryptic peptides are tagged with isobaric tags for relative and absolute 
112 
 
  
quantitation (iTRAQ) reagents and analyzed with liquid chromatography coupled to tandem 
mass spectrometry (LC-MS/MS). Differentially-expressed proteins give insight into changes in 
T-cells that affect peripheral immune function during the progression of AD. 
 
7.2 MATERIALS AND METHODS 
7.2.1 Animals  
APP/PS-1 male mice [B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, stock number 
005864, genetic background C57BL/6J express the chimeric mouse/human (Mo/Hu) APP695swe 
(i.e., K595N and M596L) and a mutant human PS1-dE9] 254 and the genetically heterogeneous 
WT (stock number 000664, genetic background C57BL/6J) were purchased from Jackson 
Laboratory and housed in the Division of Laboratory Animal Resources at the University of 
Pittsburgh. Mice were fed standard Purina rodent laboratory chow ad libitum on a 12 h light/dark 
cycle. All animal protocols were approved by the Institutional Animal Care and Use Committee 
at the University of Pittsburgh. APP/PS-1 mice and WT controls were euthanized using CO2 and 
sacrificed at three, seven, and 12 months of age (N = 6 for each genotype at each time point). 
Spleen tissues were harvested and T-cells were isolated immediately.  
 
7.2.2 T-cell Isolation and Protein Extraction  
Spleen tissue was mashed to obtain a single cell suspension. CD90.2 magnetic 
microbeads (Miltenyi Biotec, Auburn, CA, USA) were employed to positively isolate T cells 
according to the manufacturer’s instruction (hereafter referred to as CD90+ T-cells). Proteins 
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were extracted with RIPA buffer (0.05 M Tris, 0.15 M NaCl, 3 mM SDS, 10 mM Sodium 
Deoxycholate, 1 mM pheylmethylsufonyl fluoride, 1% v/v Tritan X-100, 1 µg/mL leupeptin, 1 
µg/mL pepstatin, 1 µg/mL aprotinin) and three cycles of rapid freezing and thawing was 
performed to lyse cells. Samples were centrifuged at 14,000g at 4ºC for 20 min to remove 
cellular debris. Supernatant was collected and protein concentration was determined by BCA 
assay. 
 
7.2.3 Protein Digestion and iTRAQ Labeling  
Proteins from CD90+ T-cells were acetone precipitated. Protein pellets were suspended 
in 0.1% w/v RapiGest SF (Waters, Milford, MA, USA) solution in 50mM NH4HCO3, reduced 
with dithiothreitol, alkylated with iodoacetamide, and digested with TPCK-treated trypsin 
(Sigma, St. Louis, MO, USA). Trifluoroacetic acid was added and incubated for 45 min at 37 ºC 
to quench digestion. Samples were centrifuged at 13,000 rpm for 10 min, the supernatant cleaned 
with an Oasis HLB cartridge (Waters), and dried with a SpeedVac. A pooled sample consisting 
of an equal molar amount of all samples (N = 36) was used. Each sample was labeled with an 
iTRAQ reagent following the manufacturer’s protocol (Applied Biosystems; Foster City, CA) 
with slight modifications. Briefly, each iTRAQ reagent was solubilized with 70 μL ethanol and 
transferred to peptide mixtures. After 1.5 h of incubation, the reaction was quenched by adding 
50 μL of water. Equal amounts of each iTRAQ-labeled sample were combined, cleaned with an 
Oasis HLB cartridge, and dried with a SpeedVac. 
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7.2.4 Strong Cation Exchange Fractionation and LC-MS/MS Analysis  
Offline strong cation exchange (SCX) was used to fractionate peptide mixtures as 
previously described 97. Three SCX fractions were collected and cleaned with an Oasis HLB 
cartridge (Waters; Milford, MA, USA), followed by online desalting and reverse phase 
chromatography analysis on a Nano2D- Eksigent LC system equipped with an autosampler 
(Eksigent; Dublin, CA, USA). The LC eluent was analyzed with positive ion mode nanoflow 
electrospray using a Thermo-Fisher Scientific LTQ-Orbitrap Velos mass spectrometer (Thermo 
Scientific; Waltham, MA, USA). Data-dependent acquisition parameters were: the MS survey 
scan in the Orbitrap was 60,000 resolution over 300-1800 m/z; the top six most intense peaks in 
the MS survey scan were isolated and fragmented with CID and HCD; CID was performed in the 
ion trap with normalized collision energy 35%; HCD was recorded in the Orbitrap with 
normalized collision energy 45% and 7,500 resolution; dynamic exclusion was enabled; a repeat 
count of two for a duration of 60 s was allowed and selected ions were placed on an exclusion 
list for 90 s. Each SCX fraction was subject to triplicate LC-MS/MS analysis.  
 
7.2.5 Data Analysis  
.RAW files were analyzed with Proteome Discoverer 1.3 software (Thermo Scientific; 
Waltham, MA, USA). Both CID and HCD spectra were used to obtain sequence information 
against the International Protein Index mouse database (08/16/2012, 59534 sequences).  
SEQUEST search parameters were as follows: two maximum trypsin miscleavages; precursor 
mass tolerance 10 ppm; fragment mass tolerance 0.8 Da; static modifications were iTRAQ-
8plex/+304.205 Da (N-terminus, Lys), and carbamidomethyl modification/+57.021 Da (Cys); 
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dynamic modification of oxidation/+15.995 Da (Met).  Decoy database searching was employed 
to generate medium (p < 0.05) and high (p < 0.01) confidence peptide lists. All the peptides with 
medium and high confidence were used to identify and quantify proteins. The reporter ions (i.e., 
m/z 113-119) were identified with the following parameters: centroid with smallest delta mass, 
20 ppm for reporter ion mass tolerance. The isotope correction was employed according to the 
manufacturer’s protocol (AB Sciex; Framingham, MA, USA). Additionally, protein ratios in 
each experiment were normalized based on the protein median ratio option in the software. Only 
proteins with at least two spectral counts (SCs) in a biological replicate were considered for 
further analysis.  
 
7.2.6 Statistical Analysis  
 Reporter ion ratios were obtained by comparison against the pooled sample for statistical 
testing: WT3m/pool, APP/PS-13m/pool, WT7m/pool, APP/PS-17m/pool, WT12m/pool, and APP/PS-
112m/pool. To compare protein levels between APP/PS-1 and WT mice at three, seven, and 12 
months, student’s t test was performed on proteins quantified in at least four biological replicates 
. Bonferroni multiple testing correction was applied and proteins with adjusted p-value < 0.05 
were considered as significantly different. Protein ratios were calculated by comparing a specific 
age group of APP/PS-1 mice with the respective age-matched controls as follows: (APP/PS-1 / 
WT)3m, (APP/PS-1 / WT)7m, and (APP/PS-1 / WT)12m. Fold-change cutoff values were set to 
APP/PS-1 / WT ≥ 1.30 or ≤ 0.77 as previously described 97. Finally, these proteins were grouped 
based on their biological functions. 
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7.2.7 Western Blotting Analysis 
 The changes in the expression of annexin A5, lamin B1, and aldose reductase were 
verified with Western blotting analysis. T-cell proteins (10 µg) were denatured in an appropriate 
sample buffer and electrophoretically separated on a Criterion precast gel (Biorad Laboratories; 
Hercules, CA, USA) at 140 V. Proteins from the gel were transferred onto a nitrocellulose 
membrane paper using a fast transfer blot system (Biorad Laboratories; Hercules, CA, USA). 
Blots were washed three times in wash blot. BSA blocking solution (3%) was added to the 
membrane and incubated on a rocker for 2 h. A 1 : 2500 dilution of rabbit polyclonal anti-
annexin A5 primary antibody (Abcam; Cambridge, MA, USA), 1 : 5000 dilution of rabbit 
polyclonal anti-lamin B1 primary antibody (Abcam; Cambridge, MA, USA) or 1 : 2500 dilution 
of rabbit polyclonal anti-aldose redcutase primary antibody (Santa Cruz Biotechnology, Inc; 
Dallas, Texas, USA) was added and incubated at 4°C overnight. The blot was rinsed and 
incubated with a 1 : 7500 dilution of anti-rabbit IgG alkaline phosphatase secondary antibody 
(Sigma-Aldrich; St. Louis, MO, USA) for 1 h on a rocker. The blot was rinsed and 
colorometrically developed using 0.51 mM 5-bromo-4-chloro-3′-indolylphosphate p-toluidine 
salt (BCIP) and 0.24 mM nitrotetrazolium blue (NBT). The dried blot was scanned using a 
Canon scanner, saved as a TIFF file, and densitometry analyses were carried out with Scion 
Image Software. Within each experiment, the intensity for the sample from each group was 
normalized to the total blot intensity and used to generate mean and standard deviation values. 
Student’s t test was performed on normalized band intensities.  
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7.3 RESULTS 
7.3.1 Data Characterization 
Quantitative proteomics was used to identify differentially-expressed proteins in T-cells 
during the progression of AD. Protein samples from APP/PS-1 and WT mice aged three, seven, 
and 12 months were assigned to various iTRAQ114-119 channels and a pooled sample was 
labeled with iTRAQ113 (Table 7.1). Figure 7.1 is a bar graph of the number of proteins and SCs 
identified in six biological replicate experiments. An average of 80448 ± 4735 [mean ± standard 
deviation (SD)] SCs and 411 ± 21 (mean ± SD) proteins were identified. The cumulative number 
of unique proteins identified is 927 (SC ≥ 2).  
 
7.3.2 Differentially-Expressed Proteins 
Protein ratios were obtained by comparing intensities of iTRAQ reporter ions 
corresponding to samples from APP/PS-1 mice with respective age-matched WT control mice as 
follows: (APP/PS-1 / WT)3m, (APP/PS-1 / WT)7m, (APP/PS-1 / WT)12m. Thirty-three proteins 
have significantly different levels (p < 0.05) in APP/PS-1 mice:  five, 22, and 31 proteins are 
altered at three, seven, and 12 months, respectively (Table 7.2). The number of altered T-cell 
proteins increases with progression of pathological AD hallmarks. Our study design allows us to 
assess how each individual protein varies with disease progression. For example, no significant 
difference for protein frizzled-6 (1.01 ± 0.10, p = 1.52) was observed between APP/PS-1 and 
WT mice at three months. At seven months, APP/PS-1 mice had increased levels of frizzled-6 
(1.48 ± 0.17, p = 0.02), that continued to increase at 12 months (1.85 ± 0.35, p = 2E-3). 
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  Table 7.1. iTRAQ quantitation channel assignment for each biological replicate. 
 
 
 
 
 
113 114 115 116 117 118 119
1 pool WT3mon AD3mon WT7mon AD7mon WT12mon AD12mon
2 pool WT3mon AD3mon WT7mon AD7mon WT12mon AD12mon
3 pool WT7mon AD7mon WT3mon AD3mon WT12mon AD12mon
4 pool WT7mon AD7mon WT3mon AD3mon WT12mon AD12mon
5 pool WT12mon AD12mon WT7mon AD7mon WT3mon AD3mon
6 pool WT12mon AD12mon WT7mon AD7mon WT3mon AD3mon
iTRAQ reporter ions
experiment
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Figure 7.1. Histogram of the average number (mean ± standard deviation) of proteins (gray rectangular) 
identified in each experiment. The number of spectral counts (black triangle) identified in each 
experiment and cumulative number of proteins (gray squre) identified across the six experiments are also 
shown. 
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In addition to an individual assessment of how protein expression varies, it is also 
worthwhile to understand how proteins with similar functions change with disease progression.  
There are five major pathways that differentially-expressed T-cell proteins are involved in:  
cytoskeletal structure, energy metabolism, oxidative stress, molecular chaperone activity, and 
apoptosis.  Upon grouping individual proteins into these pathways (Figure 7.2), we observe on 
average an increase in cytoskeletal structure, energy metabolism, oxidative stress, and molecular 
chaperone proteins with disease progression in APP/PS-1 mice.  Apoptosis-related proteins are 
constant on average, although it is clear (Figure 7.2 and Table 7.2) that individual proteins may 
increase or decrease with disease progression in APP/PS-1 mice.      
 
7.3.3 Western Blotting Analysis 
Three proteins, annexin A5, aldose reductase, and lamin B, were selected for Western 
blotting analysis (Figure 7.3). The relative abundances of annexin A5 obtained from iTRAQ and 
Western analysis are 1.0 : 1.0 : 1.7 : 2.8 : 2.9 : 4.6 and 1.0 : 1.2 : 1.4 : 2.6 : 2.3 : 4.0 (WT3m : 
APP/PS-13m : WT7m : APP/PS-17m : WT12m : APP/PS-112m; N = 6 and 4 for iTRAQ experiments 
and Western analysis, respectively) (Figure 7.3a). Based on good agreement across all channels 
for annexin A5 in iTRAQ experiments and Western analysis (p < 0.05), we only focused on 12-
month samples for lamin B1 and aldose reductase. The relative abundances of lamin B1 obtained 
from iTRAQ and Western analysis were 2.3 : 1.0 (N = 6, p < 0.05)  and 2.1 : 1.0 (N = 6, p < 
0.01), respectively (Figure 7.3b); the relative abundances of aldose reductase obtained from 
iTRAQ and Western analysis were 1.0 : 3.5 (N = 6, p < 0.05) and 1.0 : 2.2 (N = 6, p < 0.05), 
respectively (Figure 7.3c). Similar quantitative results were obtained between Western blotting 
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analysis and iTRAQ experiments for these proteins. Slight differences in aldose reductase ratios 
between Western and iTRAQ experiments may be caused by the suppression of iTRAQ protein 
ratios at the MS/MS level144.  Both experiments indicate that annexin A5 and aldose reductase 
levels are higher in APP/PS-1 mice at 12 months whereas lamin B1 is lower relative to WT.  
 
7.4 DISCUSSION 
 This is the first proteomics study to monitor the T-cell proteome during the progression 
of AD. While AD is a neurodegenerative disease, it is also a systemic inflammatory disease with 
elevated levels of pro-inflammatory cytokines, such as IL-6, IL-1β, and TNF-α321. Peripheral T-
cells are major contributors to this inflammation. T-cells are activated in AD and have increased 
cytokine production73,321. Alterations in the population and function of T-cells may affect a 
patient’s ability to fight against toxic Aβ products73,321. However, the molecular mechanisms for 
these alterations are not well understood. In this study, we have identified 33 differentially-
expressed proteins in CD90+ T-cells of APP/PS-1 mice at different disease stages. These 
proteins are involved in cytoskeletal structure, energy metabolism, oxidative stress, apoptosis, 
and molecular chaperone activity (Table 7.2).  
 
7.4.1 Cytoskeletal Proteins  
Cytoskeletal proteins are important for T-cell migration and activation335,339 and are 
altered in AD brain340. Upon stimulation, cytoskeleton changes T-cells from a round shape into a 
migrating morphology. Once T-cells bind to antigen presenting cells, they change shape into a  
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Figure 7.2. Illustrative depiction of biological pathways in which differentially-expressed T-cell proteins 
during AD progression are invovled. Dotted lines corresponse the fold-change for individual protein in 
each biological pathway. Red lines are the average fold-change for all proteins involved in each biological 
pathway. 
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Figure 7.3. Examples of reporter ion intensities (top panel) and Western blotting images (bottom panel) 
for a) annexin A5, b) lamin B1, and c) aldose reductase. The histogram under the Western blotting 
images displays the normalized intensity ± standard deviation (N = 4, 6, 6 for annexin A5, lamin B1 and 
aldose reductase, respectively) across each group. The intensity for each individual band is normalized to 
the total intensity of the blot. * p < 0.01 and ** p < 0.05. 
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     Table 7.2. List of differentially-expressed T-cell proteins in APP/PS-1 mice. 
 
 
3 months 7 months 12 months
1.31 ± 0.12 1.07 ± 0.08 1.51 ± 0.22
(p =  2E-3) (p =  2.15) (p =  0.02) 
0.97 ± 0.10 1.10 ± 0.13 1.53 ± 0.43
(p =  10.58) (p =  9.50) (p =  3E-5)
1.02 ± 0.10 1.48 ± 0.17 1.85 ± 0.35
(p =  1.52) (p =  0.02) (p =  2E-3)
1.06 ± 0.10 1.13 ± 0.28 1.43 ± 0.11
(p =  10.2) (p = 13.20) (p =  0.04)
1.37 ± 0.34 1.10 ± 0.22 1.46 ± 0.29
(p =  0.03) (p =  32.83) (p =  0.02)
0.94 ± 0.17 1.25 ± 0.26 1.47 ± 0.36
(p =  18.48) (p =  0.02) (p =  8E-4)
0.87 ± 0.12 0.98 ± 0.33 1.70 ± 0.45
(p =  13.53) (p =  7.92) (p =  9E-3)
0.89 ± 0.16 1.45 ±0.17 1.52 ± 0.32
(p =  20.46) (p =  6E-3) (p =  0.04)
0.95 ± 0.13 1.40 ± 0.16 1.64 ± 0.14
(p =  21.78) (p =  0.03) (p =  1E-3)
0.96 ±0.29 1.45 ± 0.32 1.50 ± 0.46
(p =  19.80) (p =  0.02) (p =  0.02)
1.30 ± 0.19 0.86 ±0.14 1.36 ± 0.11
(p =  9E-4) (p =  19.85) (p =  1E-3)
0.88 ±0.17 1.69 ±0.24 1.94 ± 0.43
(p =  22.44) (p =  0.03) (p =  3E-6)
1.02 ± 0.19 1.42 ± 0.58 1.89 ± 0.59
(p =  25.74) (p =  0.04) (p =  4E-4)
0.85 ± 0.20 1.27 ±0.33 1.40 ± 0.32
(p =  14.85) (p =  10.56) (p =  0.03)
0.79 ±0.16 2.00 ± 0.34 2.28 ± 0.46
(p =  18.81) (p =  0.02) (p =  6E-5)
1.04 ± 0.27 1.26 ± 0.48 1.63 ± 0.50
(p =  17.49) (p =  0.02) (p =  0.02)
IPI00407130.4 pyruvate kinase energy 
metabolism
IPI00555069.3 phosphoglycerate kinase 1 energy 
metabolism
IPI00323592.2 malate dehydrogenase 2 energy 
metabolism
IPI0033632.11 malate dehydrogenase 1 energy 
metabolism
IPI00380895.7 myosin-3 cytoskeletal 
structure
IPI00399943.3 actin-related protein 2/3 
complex subunit 5
cytoskeletal 
structure
IPI00230395.5 annexin A1 cytoskeletal 
structure
IPI00317309.5 annexin A5 cytoskeletal 
structure
IPI00138691.6 actin-related protein 2/3 
complex subunit 4
cytoskeletal 
structure
IPI00177038.1 actin-related protein 2 cytoskeletal 
structure
IPI00123181.4 myosin-9 cytoskeletal 
structure
IPI00136110.4 phosphatidylinositol-4,5-
bisphosphate 3-kinase 
cytoskeletal 
structure
IPI00117095.1 frizzled-6 cytoskeletal 
structure
IPI00117352.1 tubulin beta-5 chain cytoskeletal 
structure
IPI00109044.8 myosin light chain, 
regulatory B-like
cytoskeletal 
structure
IPI00110588.4  moesin cytoskeletal 
structure
IPIa Protein Description
Fold change (APP/PS-1 / WT)b 
Functionc
125 
 
  
  
3 months 7 months 12 months
1.08 ±0.33 1.26 ± 0.27 1.47 ± 0.53
(p =  3.75) (p =  0.03) (p =  0.02)
1.22 ± 0.13 1.42 ± 0.25 2.16 ± 0.48
(p =  9.25) (p =  4E-3) (p =  0.02)
1.05 ± 0.14 1.20 ± 0.26 1.43 ± 0.35
(p =  4.15) (p =  10.28) (p =  0.03)
1.09 ±0.11 1.25 ±0.41 1.45 ± 0.32
(p =  8.58) (p =  11.55) (p =  0.02)
0.98 ± 0.26 1.57 ± 0.32 1.44 ± 0.65
(p =  20.46) (p =  2E-3) (p =  0.03)
0.92 ±0.28 1.11 ±0.55 1.36 ± 0.63
(p =  10.56) (p =  19.14) (p =  0.02)
0.82 ±0.29 1.44 ± 0.34 1.62 ± 0.58
(p =  13.53) (p =  0.04) (p =  0.02)
0.81 ± 0.41 0.68 ± 0.27 0.48 ± 0.20
(p = 7.59) (p =  0.03) (p =  0.02)
0.80 ± 0.32 0.70 ± 0.27 0.59 ± 0.20
(p =  2.64) (p =  0.02) (p =  0.02)
1.06 ± 0.49 1.39 ± 0.48 1.55 ± 0.62
(p =  4.95) (p =  0.04) (p =  3E-4)
1.05 ± 0.25 1.23 ± 0.36 1.36 ± 0.16
(p =  5.94) (p =  9.57) (p =  0.03)
0.88 ± 0.26 1.36 ±0.47 2.27 ±0.89
(p =  11.88) (p =  0.03) (p =  0.05)
0.91 ± 0.22 1.60 ± 0.82 1.48 ± 0.49
(p =  28.05) (p =  0.03) (p =  0.04)
0.89 ± 0.27 1.32 ± 0.56 1.70 ± 0.61
(p =  8.58) (p =  0.04) (p =  4E-3)
0.89 ± 0.31 1.54 ±0.49 0.70 ± 0.24
(p =  19.80) (p =  0.03) (p =  0.02)
0.48±0.27 0.58±0.32 0.63 ± 0.39
(p =  0.04) (p =  0.03) (p =  0.03)
0.47±0.17 0.71±0.23 0.80 ± 0.17
(p =  0.02) (p =  0.04) (p =  1.52)
oxidative 
stress
IPI00117910.3 peroxiredoxin-2 oxidative 
stress
IPI00130589.8 superoxide dismutase [Cu-
Zn]
oxidative 
stress
a protein ID provided by international protein index (IPI) database (08/16/2012, 59534 sequences).
b protein fold-change values are shown as average ± standard deviation (n=6); p-value was obtained 
c protein functions are obtained from literature and uniprot
IPI00648105.1 uncharacterized protein /
IPI00123570.3 putative uncharacterized 
protein
/
IPI00554929.3 heat shock protein HSP 90-
beta
molecular 
chaperone
IPI00462291.5 high mobility group box1 granzyme A 
signaling
IPI00323357.3 heat shock cognate 71 kDa 
protein
molecular 
chaperone
IPI00330804.4 heat shock protein HSP 90-
alpha
molecular 
chaperone
IPI00308885.6 isoform 1 of 60 kDa heat 
shock protein, 
molecular 
chaperone
IPI00319992.1 78 kDa glucose-regulated 
protein
molecular 
chaperone
IPI00230394.5 lamin-B1 apoptosis
IPI00466069.3 elongation factor 2 apoptosis
IPI00123886.2 isoform 1 of DNA-
dependent protein kinase 
apoptosis
IPI00223713.5 histone H1.2 apoptosis
IPI00223757.4 aldose reductase oxidative 
stress
IPI00759999.1 isoform 
cytoplasmic+peroxisomal of 
oxidative 
stress
  ( )    y p   p    
IPI Protein Description
Fold change (APP/PS-1 / WT)
Function
IPI00113996.7 flavin reductase
Table 7.2. (continued) List of differentially-expressed T-cell proteins in APP/PS-1 mice. 
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stopped morphology and are activated335. Alterations in T-cell cytoskeletal proteins may affect 
migration. For example, moesin is a member of ezrin-radirin-moesin protein family, which is an 
important component of actin-based cytoskeleton. T-cells which are moesin-deficient or have 
low levels of moesin have reduced migration341,342. On the other hand, CD4+ T-cells isolated 
from the elderly have increased migration that may be explained by elevated levels of myosin 
IIA330. 
In this study, 12 cytoskeletal proteins are differentially-expressed during the progression 
of AD (Table 7.2). Five proteins have significantly increased concentrations in APP/PS-1 mice at 
seven and 12 months. Annexin A5 had higher concentrations in seven (1.45 ± 0.32, p = 0.02) 
and 12 (1.50 ± 0.46, p = 0.02) month-old APP/PS-1 mice compared to WT. Elevated levels of 
four proteins (i.e., moesin, tubulin beta-5 chain, actin-related protein 2/3 complex subunit 4) are 
only observed in 12 month-old APP/PS-1 mice. Increased levels of cytoskeletal proteins (e.g., 
cofilin-1 and actin) are observed in lymphocytes from PD patients343. These results correlate with 
increased migration of T-cells toward the brain in AD73. Although the mechanism for this 
migration is still unclear, neuroinflammation in AD may signal T-cell trafficking toward the 
brain73,321. Over-expression of C-X-C motif chemokine receptor 2344 and macrophage 
inflammatory protein-1α345 mediate the transendothelial migration of T-cells. Systemic 
inflammation associated with AD may also increase the migration of T-cells. In this case, T-cells 
would travel throughout the body to scan for antigens346. In addition, cytoskeletal proteins are 
involved in immune cell activation347. Increased levels of cytoskeletal proteins in our proteomics 
studies are consistent with elevated activation makers on T-cells during AD progression266.  
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7.4.2 Energy Metabolism 
 Altered energy metabolism is a widely accepted phenomenon in AD348-352. Differential 
expression of energy-related genes (e.g., genes coding NADH dehydrogenase and succinate 
dehydrogenase) and proteins (e.g., ATP synthase, α-enolase, malate dehydrogenase) is associated 
with neuronal and synaptic loss in AD349-352. Aging influences energy metabolism in 
lymphocytes339,353. We observe higher levels of energy metabolism-related proteins in APP/PS-1 
mice at later disease stages: phosphoglycerate kinase 1 (PGK-1) [(APP/PS-1 / WT)7m: 1.26 ± 
0.48, p = 0.02; (APP/PS-1 / WT)12m: 1.63 ± 0.50, p = 0.02], pyruvate kinase (PK) [(APP/PS-1 / 
WT)7m: 2.00 ± 0.34, p = 0.02; (APP/PS-1 / WT)12m: 2.28 ± 0.46, p = 6E-5], malate 
dehydrogenease 1 (MDG-1) [(APP/PS-1 / WT)12m: 1.40 ± 0.32, p = 0.03], and malate 
dehydrogenease 2 (MDG-2) [(APP/PS-1 / WT)7m: 1.42 ± 0.58, p =0.04; (APP/PS-1 / WT)12m: 
1.89 ± 0.59, p = 4E-4]. 
 PGK-1 and PK catalyze the formation of ATP in glycolysis 354. MDG-1 and MDG-2 
reduce NAD+ to NADH, another form of energy. Elevated levels of PK and MDG-2 occur in 
APP/PS-1 mice compared to WT at seven and 12 months, and PGK-1 and MDG-1 have 
relatively higher concentrations at 12 months. These findings suggest elevated energy 
metabolism in AD T-cells, which is likely necessary for the production of cytokines and 
increased migration during AD progression. Similarly, microglia and astrocytes have increased 
activity of metabolic enzymes (e.g., pyruvate kinase) in AD355. This phenomenon also exists in 
lymphocytes from PD patients343.  
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7.4.3 Oxidative Stress and Apoptosis 
 Oxidative stress plays a key role in the pathogenesis of AD, PD, HD, ALS, DS, and 
multiple sclerosis356. AD brain is characterized by protein oxidation, lipid peroxidation, DNA 
and RNA oxidation, and higher levels of reactive oxygen species303,319. Recently, we observed 
that oxidative stress in AD extends to the periphery336. Elevated oxidative stress as measured by 
protein carbonyls and 3-nitrotyrosine occurs in CD90+ T-cells from APP/PS-1 mice with disease 
progression336. Herein, five proteins involved in the redox process have altered levels (Table 
7.2). Flavin reductase and peroxiredoxin-2 have increased levels in APP/PS-1 mice beginning at 
seven months and at 12 months (flavin reductase: 1.47 ± 0.53, p = 0.02; peroxiredoxin-2: 2.16 ± 
0.48, p = 0.02) (Table 1). Increased levels of superoxide dismutase [Cu-Zn] (SOD) (1.43 ± 0.32, 
p = 0.03) and aldose reductase (1.45 ± 0.32, p = 0.02) are observed at 12 months in APP/PS-1 
mice. Both SOD and aldose reductase are a part of the cellular antioxidant defense system. 
Increased levels of SOD and aldose reductase have been reported in AD brain303,319. Consistent 
findings in T-cells have been reported. T-cells from AD patients have increased levels of 8-
hydroxy-2’-deoxyguanosine301, oxidized purines357, and decreased levels of glutathione358. T-
cells have diminished ability to repair oxidative damage357. Our proteomics results of changes in 
redox proteins provide further evidence for oxidative stress in CD90+ T-cells with AD 
progression.  
Oxidative stress can induce apoptosis359. Increased apoptosis of lymphocytes occurs in 
AD patients360-362. Four proteins involved in apoptosis are differentially-expressed herein: 
isoform 1 of DNA-dependent protein kinase catalytic subunit [DPKC; (APP/PS-1 / WT)12m: 1.36 
± 0.63, p = 0.02], elongation factor-2 [EF-2; (APP/PS-1 / WT)7m: 0.70 ± 0.27, p = 0.02; 
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(APP/PS-1 / WT)12m: 0.59 ± 0.20, p = 0.02], lamin B1 [LMNB1; (APP/PS-1 / WT)7m: 0.68 ± 
0.27, p = 0.03; (APP/PS-1 / WT)12m: 0.48 ± 0.20, p = 0.02], and histone H1.2 [HH1.2; (APP/PS-
1 / WT)7m: 1.44 ± 0.34, p = 0.04; [(APP/PS-1 / WT)12m: 1.62 ± 0.58, p = 0.02]. Elevated DPKC 
levels in AD brain correlate with oxidative stress363. Decreased levels of EF-2, which has anti-
apoptotic properties, are associated with CD4+ T-cells in HIV patients364. EF-2 is inactive in 
cortex and hippocampus of AD patients and may cause neuronal death365. Lower concentrations 
of LMNB1 induce apoptosis366,367 and translocation of HH1.2 from nucleus into the cytoplasm 
368. Reduced levels of HH1.2 increase resistance to apoptosis369.  In AD brain, neurons and 
astrocytes have elevated levels of HH1.2 which could contribute to neuronal death370-372. Our 
results suggest that T-cells from APP/PS-1 mice have increased apoptosis consistent with other 
findings in this model 373 and in PD, HD, and DS374-376. Increased apoptosis may induce 
immunosuppression in patients with neurodegenerative disorders377, however, further 
experiments are necessary to support this notion. 
 
7.4.4 Molecular Chaperones 
 Heat shock proteins (HSPs) are molecular chaperones which are responsible for the 
folding, degradation and translocation of proteins, and protection of cells in stressed conditions 
(e.g., heat and oxidative stress)377. Age-related expression of HSPs occurs 378. HSPs accumulate 
in brains of patients with AD, PD, and ALS as a result of oxidative stress and higher levels of 
misfolded proteins379,380. Elevated levels of stress-related proteins in lymphocytes are correlated 
with risk of AD381. In this study, five HSPs have higher levels in APP/PS-1 mice after disease 
onset: isoform 1 of 60 kDa heat shock protein [(APP/PS-1 / WT)7m: 1.39 ± 0.48, p = 0.04; 
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(APP/PS-1 / WT)12m: 1.55 ± 0.62, p = 3E-4], 78 kDa glucose-regulated protein [(APP/PS-1 / 
WT)12m: 1.36 ± 0.16, p = 0.03], heat shock cognate 71 kDa protein [(APP/PS-1 / WT)7m: 1.36 ± 
0.47, p =0.03; (APP/PS-1 / WT)12m: 2.27 ± 0.89, p = 0.05], heat shock protein HSP 90α 
[(APP/PS-1 / WT)7m: 1.60 ± 0.82, p =0.03; (APP/PS-1 / WT)12m: 1.48 ± 0.49, p = 0.04], and heat 
shock protein HSP 90β [(APP/PS-1 / WT)7m: 1.32 ± 0.56, p =0.04; (APP/PS-1 / WT)12m: 1.70 ± 
0.61, p = 4E-3]. HSP expression in T-cells could be elevated in response to oxidative stress 
and/or apoptosis75,382. HSPs play important roles in regulating the immune system and are crucial 
in T-cell activation, proliferation, and cytokine production383. It is possible that T-cells are 
activated and that there is higher cytokine production in APP/PS-1 mice. Further studies are 
necessary to understand how HSPs regulate T-cell function in AD.  
 
7.5 CONCLUSIONS 
In summary, we have monitored the CD90+ T-cell proteome in APP/PS-1 mice with 
disease progression. Cytoskeletal, energy metabolism, oxidative stress, apoptosis, and molecular 
chaperone proteins are generally higher in expression in APP/PS-1 mice relative to age-matched 
controls. Proteome changes suggest T-cell activation, oxidative stress and response to stress with 
chaperones, higher energy metabolism necessary for cell migration, and apoptosis are prevalent 
in peripheral cells with disease progression. This study gives insight to the fact that AD is 
characterized by global changes outside of the CNS which may explain premature 
immunosenescence and increased susceptibility to infection in AD patients. One limitation for 
this study is that male mice are employed to investigate the peripheral immune system in AD. 
131 
 
  
Further studies are necessary to determine how the proteome alterations and gender influence T-
cell function in the APP/PS-1 mouse model.  
 
(It should be noted that at the time of dissertation submission data related to the work in this 
chapter are unrecoverable) 
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8.0 FUTURE DIRECTIONS 
8.1 SUMMARY 
        Previous chapters have described the development of novel proteomics methods and the 
application of proteomics tools to understand roles of immunosenescence in aging-related 
diseases, sepsis and AD. In Chapter 2, a quantitative proteomics workflow for human plasma 
including TMD, protein digestion, iTRAQ labeling, SCX fractionation, and RPLC-MS/MS 
analysis was developed. This workflow allows for the detection of novel plasma proteins which 
have not been reported previously. In addition, a statistical model was established which 
provides information for the determination of differentially-expressed proteins and further 
experimental design (e.g., number of biological replicates required). Chapter 3 shows a novel 
PQD-MS3-based data acquisition method for isobaric tag quantitation. This method increases the 
number of identified and quantified proteins and peptides with high quantitative accuracy. PQD-
MS3 also offers a mean to quantify proteins on low resolution mass spectrometry instruments 
(e.g., LTQ).  
         In Chapter 4, the quantitative proteomics workflow for human plasma developed in 
Chapter 2 was applied to understand the molecular mechanisms associated with aging-related 
risk of severe sepsis among CAP patients. In this study, biological pathways which have been 
well studied in sepsis are identified. This confirms the value of proteomics tools in studies about 
pathological conditions. More importantly, novel pathways were also found in this study, for 
example, lipid metabolism and atherosclerosis signaling. Differentially-regulated biological 
pathways between younger (i.e., 55-65 years old) and older (i.e., 75-85 years old) adults may 
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explain the aging-related risk of severe sepsis. For example, compared to the corresponding CAP 
patients, the younger severe sepsis patients have hyper-inflammation and -coagulation whereas, 
the older severe sepsis patients have hypo-inflammation and -coagulation.       
            In AD studies, proteome of splenocytes from APP/PS-1 mice at advanced stage of AD is 
first characterized. This study provides a protein reference map for further investigation of 
peripheral immune system in AD. Using immunoblotting analysis techniques, increased 
oxidative stress in splenocytes during AD progression are found. Proteomics studies about 
alterations in T-cell proteins provide molecular basis for this increased oxidative stress. In 
addition, other biological pathways, such as cytoskeleton, energy metabolism, apoptosis, and 
molecular chaperones, are identified in AD progression. 
        Overall, proteomics methods developed in this dissertation increase the number of identified 
and quantified proteins, which is helpful for the discovery of novel disease biomarkers. 
Application of proteomics tools to the studies of sepsis and AD reveals additional information 
about the roles of immune system in sepsis and AD. Furthermore, these results are helpful to 
initiate follow-up projects, which will provide more complete and accurate picture of aging-
related diseases.  
 
8.2 FUTURE DIRECTIONS 
8.2.1 Understanding the Effects of Proteome Alterations on Immune System Functions  
            Chapter 4 provides a list of proteins that have altered concentrations due to the severity 
of septic infection (i.e., severe sepsis vs. CAP). Out of these proteins, eight differentially-
expressed proteins are identified in both younger and older patient groups. Interestingly, all of 
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these proteins show different regulation directions between these two age groups. For example, 
positive acute phase proteins (i.e., C-reactive protein, LPS-binding protein, and alpha-1-
antichymotrypsin) have increased levels in the younger severe sepsis patients but decreased 
levels in the older severe sepsis patients. Changes in these acute phase proteins show that hyper- 
and hypo-inflammation are associated with the younger and older severe sepsis patients, 
respectively. However, no direct results regarding the alterations of immune cell functions are 
provided in this study. I hypothesize that the hyper- and hypo-inflammation in the younger and 
older severe sepsis patients may be related to their over-reactivity of immune system and 
immunosuppression, respectively. Due to the difficulty to access human samples, a sepsis mouse 
model, cecal ligation puncture (CLP) mouse, can be used. Twelve and 24 hours after CLP 
surgery correspond to the early and late phase of sepsis, respectively. Four groups of CLP mouse 
can be generated: six-month old mice (mimicking the younger adult patients) at 12 and 24 hours 
after CLP surgery and 14-month old mice (mimicking older adult patients) at 12 and 24 hours 
after CLP surgery. The intracellular levels of IL-2 and IFN-γ (two activation markers of immune 
cells) in T-cells and other immune cells (e.g., B-cells and macrophages) can be compared across 
these four groups.  
             Chapter 7 presents the changes in T-cell proteome during AD progression and increased 
levels of proteins involved in cytoskeleton, energy metabolism, oxidative stress, apoptosis, and 
chaperones are found. Further studies are necessary to gain better insight into how these 
alterations affect the function of T-cells. For example, increased levels of cytoskeletal proteins 
may be related to the increased migration of T-cells found in AD patients73. However, the 
migration of T-cells in APP/PS-1 mice has not been investigated yet. Another follow-up project 
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is the investigation of how apoptosis affects the function of T-cells in AD. Apoptosis of immune 
cells has been suggested to induce immunosuppression384. Therefore, it is worthwhile to measure 
the relation between the levels of apoptosis markers (e.g., Bax, B-cell lymphoma 2, and caspase-
3) and activity markers (e.g., IL-2 and IFN-γ) in T-cells from APP/PS-1 mice. In addition, 
increased plasma levels of anti-inflammatory cytokines in APP/PS-1 mice can be used as 
additional evidence for immunosuppression.    
 
8.2.2 Development of Novel Treatments to Decrease the Mortality of Sepsis or to Slow the 
Progression of AD 
         Different biological pathways have been identified to be associated with the age-related 
risk of severe sepsis among CAP patients in Chapter 4. Among these, four pathways related to 
retinoid X receptor (RXR) are identified: liver X receptor (LXR)/RXR activation, farnesoid X 
receptor (FXR)/RXR activation, LPS/IL-1 mediated inhibition of RXR function, and peroxisome 
proliferator-activated receptor alpha (PPARα)/RXRα activation. RXR plays a central role in the 
nuclear receptor superfamily because it forms heterodimers with many other nuclear receptors 
and therefore are involved in a variety of physiological processes including immune response385. 
For example, in the innate immune system, activation of RXR prevents the apoptosis and 
inflammatory response of macrophages386. In the adaptive immune system, RXR regulates the 
differentiation of T-cells into regulatory or helper T-cells387. Knockout of RXR gene results in 
diminished proliferation and increased apoptosis in T-cells388. In addition, RXR protects human 
endothelial cells from oxidative stress induced by high-dose glucose389. In sepsis, infection-
induced damage to liver is reduced by the activation of RXR390. However, the effects of RXR on 
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T-cells in septic infection have not been examined yet. I hypothesize that activation of RXR may 
protect T-cells from oxidative stress induced by infection (e.g., LPS stimulation). To test this 
hypothesis, CD4+ T-cells were isolated from the spleen of 6-month wild type mice. These cells 
were cultured in medium with or without LPS-stimulation for 24 hours. As shown in Figure 8.1a, 
LPS-stimulated CD4+ T-cells have increased levels of oxidative stress compared to controls. 
Increased levels of RXR are also observed in LPS-stimulated CD4+ T-cells (Figure 8.1b). 
Increased levels of RXR might be responsible for the increased protein expression induced by 
LPS in CD4+ T-cells. For example, Apo E is a gene target for RXR389. Increased plasma 
concentrations of ApoE were observed in severe sepsis patients at 55-65 years old (Chapter 4). 
This process may require higher levels of RXR. However, further experiments are necessary to 
test the correlation between ApoE and RXR levels in response to infection. Additionally, the 
effects of aging on the roles of RXR in T-cells can be tested.     
        In Chapter 7, multiple biological pathways are altered in T-cells during the progression of 
AD. Combination of different therapies may provide a more effective means to treat AD. 
Antioxidant (e.g., vitamin C and N-acetylcysteine) and anti-apoptotic (e.g., humanins and 
statins) drugs have been reported separately to reduce the accumulation of Aβ plaques and slow 
the progression of AD391,392.  The combination of antioxidant and anti-apoptotic drugs can be 
tested. The effects of this combined treatment on AD should be compared with each individual 
treatment.  
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Figure 8.1. Increased levels of a) oxidative stress and b) RXR in CD4+ T-cells stimulated with LPS. 
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8.3 CONCLUDING REMARKS 
      The role of immunosenescence in aging-related diseases is one of the most popular but 
challenging scientific topics. Herein, works presented in this dissertation investigated alterations 
associated with the immune system in sepsis and AD using proteomics technologies. Findings 
from these works provide insight into the molecular mechanisms associated with sepsis and AD 
from the prospective of immune system.  
      Firstly, results from sepsis studies imply that age is an important factor affecting host 
response to sepsis. Hyper- and hypo-inflammatory response is found in the younger and older 
severe sepsis patients, respectively. These findings suggest that doctors need to be cautious when 
interpreting clinical data from sepsis patients at different ages. For example, high plasma 
concentrations of CRP may lead to the development of severe sepsis in younger CAP patients 
but low CRP concentrations may indicate poor outcome in older CAP patients. These 
observations also suggest that different treatments need to be performed based on the ages of 
sepsis patients.  
         Secondly, in APP/PS-1 mouse, splenocytes have increased oxidative stress during the 
progression of AD. Altered levels of T-cell proteins involved in oxidative stress provide 
molecular mechanisms for this phenomenon. Increased apoptosis, migration and energy 
metabolism in T-cells are also found in the progression of AD. These results confirm that 
alterations of the peripheral immune system do occur during the progression of AD. Findings 
from these studies also warrant further investigation of the changes of T-cell functions in AD. 
        Overall, this dissertation confirms that alterations in the immune system may contribute to 
the pathogenesis of aging-related diseases-sepsis and AD. Additionally, novel insight to 
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molecular changes associated with septic infection and AD has been gained. Besides the 
proteomics technologies, tools in genomics, transcriptomics, and metabolomics should be 
employed to further systematically investigate immunosenescence in sepsis and AD. Insight 
obtained from these studies should be helpful for the development of novel methods for the 
prevention and treatment of sepsis and AD.      
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